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The advance in cancer early detection and cancer treatment have led to the rapid growth in
the number of cancer survivors. It is good news that cancer is more survivable than ever,
however, it also brings new challenges. Cancer survivors are exposed to the risk of a second
primary cancer. In Chapter 1 and Chapter 3, we investigated the survival of lung cancer patients
with a history of previous cancer. Another challenge that cancer survivors need to face is the
follow-up care. Many survivors found that they are “lost in transition” from cancer patients to
cancer survivors. In Chapter 2, we investigated the patterns of use and impact on emergency
department utilization in a comprehensive cancer survivorship program.

v

TABLE OF CONTENTS

LIST OF FIGURES …………………………………………………………………………viii
LIST OF TABLES ……………………………………………………………………………ix
............................................................................................................................... 1
1.1 Introduction ....................................................................................................................... 1
1.2 The Lung Cancer Data ...................................................................................................... 3
1.3 Methods............................................................................................................................. 5
1.3.1 The LS/NB Model...................................................................................................... 5
1.3.2 Estimation .................................................................................................................. 8
1.3.3 Sensitivity Analysis ................................................................................................... 9
1.4 Results ............................................................................................................................. 10
1.4.1 Preliminary Analyses ............................................................................................... 10
1.4.2 LS/NB Model Estimates .......................................................................................... 11
1.4.3 Sensitivity Analyses ................................................................................................. 23
1.5 Discussion ....................................................................................................................... 23
1.5.1 Summary and Context.............................................................................................. 23
1.5.2 Modeling Issues ....................................................................................................... 24
vi

1.5.3 Clinical Implications ................................................................................................ 27
............................................................................................................................. 28
2.1

Introduction ................................................................................................................ 28

2.2

Materials and Methods ............................................................................................... 30
Study procedures ................................................................................................. 30
Statistical analysis ............................................................................................... 32

2.3

Results ........................................................................................................................ 36

2.4

Discussion ................................................................................................................... 43
............................................................................................................................. 46

3.1

Introduction ................................................................................................................ 46

3.2

Methods ...................................................................................................................... 49
Data Source ......................................................................................................... 49
Study Population ................................................................................................. 49
Measures.............................................................................................................. 50
Statistical Analysis .............................................................................................. 51

3.3

Results ........................................................................................................................ 53

3.4

Discussion ................................................................................................................... 58

BIBOLOGRAPHY ................................................................................................................... 61
APPENDIX ……………………………...………………………………………...………….67

vii

LIST OF FIGURES

Figure 1-1. Kaplan-Meier survival curves (on the log scale) for newly diagnosed lung cancer
patients, stratified by stage ........................................................................................ 14
Figure 1-2. Raw (KM) and estimated hazard functions of lung cancer–specific and overall
survival in the No-Previous group, stratified by stage. KM, Kaplan-Meier; LS/NB,
Logit-Spline/Negative Binomial ............................................................................... 15
Figure 1-3. Estimated survival functions (on the log scale) by Kaplan-Meier (KM) and the LogitSpline/Negative Binomial (LS/NB) method, stratified by stage ............................... 18
Figure 1-4. Cumulative incidence curves for stage I&II and stage IV (stage III is similar to stage
IV) ............................................................................................................................. 21
Figure 1-5. Estimated mean lead time (in month) as a function of odds ratio (OR), by stage ..... 22
Figure 1-6. Analysis of sensitivity of 𝐸[𝑇] (in months) to assumed independence of 𝑇 and 𝑋𝑃. 22
Figure 2-1. k-means clusters visualized in principal components coordinates. (PC1-PC4: the first
four principal components) ....................................................................................... 40
Figure 2-2. Participation in different type of survivorship services by cluster type. Panel A shows
the proportion of all visits by visit type and Panel B shows the average number of
visits by visit type. ..................................................................................................... 42
Figure 2-3. Effect of participation in the survivorship program on ratio (the number of ED visits
in the intervention group to that in the reference group) of emergency department
(ED) visits. Panel A shows the effect of participants in the program vs. participants
before program and matched non-participants (reference group). Panel B shows the
effect of different clusters of participation among participants only, comparing the
ratio of ED visits after program participation to the ratio before program
participation (reference group). A ratio of 1.0 indicates that the number of ED visits
in the intervention group is the same as the reference group. A ratio less than 1.0
demonstrates fewer ED visits in the intervention vs. reference group. ..................... 43
Figure 3-1. Cumulative incidence rate of death by stage and cause of death in the three-cause
data for lung cancer patients with and without previous cancer. .............................. 57
Figure S1. Cumulative incidence rate by stage and cause of death in the two-cause data for lung
cancer patients with and without previous cancer. ..................................................... 69
viii

LIST OF TABLES

Table 1-1. Tabular representation of the Surveillance, Epidemiology, and End Results–Medicare
lung cancer data ............................................................................................................ 7
Table 1-2. Surveillance, Epidemiology, and End Results–Medicare data: count of patients by
stage and previous cancer diagnosis ........................................................................... 11
Table 1-3. Surveillance, Epidemiology, and End Results–Medicare lung cancer data: summary of
mortality in the matched data ...................................................................................... 11
Table 1-4. Estimated lung cancer–specific and all-cause survival in months (%) for the NoPrevious group ............................................................................................................ 16
Table 1-5. Estimated mean lead time E[T] (month) and OR, by cause of death and stage .......... 20
Table 1-6. Sensitivity analysis of estimates of OR (assuming 𝑇 ≡ 0) and mean lead time 𝐸(𝑇)
(for fixed OR) ............................................................................................................. 21
Table 1-7. Sensitivity to the assumed lead-time distribution ........................................................ 23
Table 2-1. Summary statistics of participants and non-participants ............................................. 37
Table 3-1. Characteristics of patients with stage I&II lung cancer. .............................................. 54
Table 3-2. Mortality fraction by lung cancer stage and cause of death. ....................................... 55
Table 3-3. Estimated mean lead time (months) and odds ratios by cause of death and stage in the
three-cause competing risk data. .................................................................................. 57
Table S1. Characteristics of patients with stage III lung cancer. ................................................. 67
Table S2. Characteristics of patients with stage IV lung cancer................................................... 68
Table S3. Estimated mean lead time (months) and odds ratios by cause of death and stage in the
two-cause competing risk data. .................................................................................... 70

ix

Surprisingly, survival from a diagnosis of lung cancer has been found to be longer for those
who experienced a previous cancer than for those with no previous cancer. A possible
explanation is lead-time bias, which, by advancing the time of diagnosis, apparently extends
survival among those with a previous cancer even when they enjoy no real clinical advantage.
We propose a discrete parametric model to jointly describe survival in a no-previous-cancer
group (where, by definition, lead-time bias cannot exist) and in a previous-cancer group (where
lead-time bias is possible). We model the lead time with a negative binomial distribution and the
post–lead-time survival with a linear spline on the logit hazard scale, which allows for survival to
differ between groups even in the absence of bias; we denote our model Logit-Spline/Negative
Binomial. We fit Logit-Spline/Negative Binomial to a propensity-score matched subset of the
Surveillance, Epidemiology, and End Results–Medicare linked data set, con-ducting sensitivity
analyses to assess the effects of key assumptions. With lung cancer–specific death as the end
point, the estimated mean lead time is roughly 11 months for stage I&II patients; with overall
survival, it is roughly 3.4 months in stage I&II. For patients with higher-stage lung cancers, the
mean lead time is 1 month or less for both outcomes. Accounting for lead-time bias reduces the
survival advantage of the previous-cancer group when one exists, but it does not nullify it in all
cases.
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1.1 Introduction
Lung cancer, with 5-year survival less than 20%, is the leading cause of cancer-related death
in the United States.1 It mainly affects older people, many of whom have experienced previous
cancers and other chronic diseases. Indeed, in 1992-2009 linked Surveillance, Epidemiology, and
End Results (SEER) – Medicare data, the proportion of lung cancer patients who were survivors
of another cancer at the time of their lung cancer diagnosis ranged from 14% to 21%, depending
on stage.2-4 Because a previous diagnosis of cancer is thought to adversely affect clinical
outcomes, it is a common exclusion criterion in lung cancer clinical trials, blocking up to 18% of
otherwise eligible patients from participation.5 Yet surprisingly, several studies have reported
that among newly diagnosed lung cancer patients aged 66 and older, those with a previous cancer
do not have worse survival than those with no previous diagnosis; indeed, they often do
better.2,3,6-8 For example, Laccetti et al2 observed that among patients with a newly diagnosed
stage IV lung cancer, those with a previous cancer diagnosis had longer all-cause survival and
lung cancer–specific survival than similar patients who had not had a previous cancer.
A possible explanation is lead-time bias. Lead time is the length of time between the moment
a disease becomes detectable (that is, by tests applied to an asymptomatic person) and the
moment it becomes clinically manifest. If a lead time advances the date of diagnosis, the survival
time will appear to be longer, even if earlier detection offers no clinical benefit. It is plausible
that a lead-time bias could exist in the case of a cancer survivor, likely as a result of enhanced
surveillance or the patient's seeking prompt evaluation of symptoms that could represent a
subsequent tumor.
Statisticians have long recognized the potential biasing effects of early detection on apparent
cancer survival9-11; consequently, statistical models of lead-time bias largely assume the
2

background of a cancer screening program.12-14 In this paper, we propose a parametric method
for estimating lead-time bias that has arisen not from formal screening but instead from whatever
additional surveillance that patients and their doctors have implemented following a previous
cancer diagnosis. We suppose that one has data from newly diagnosed lung cancer patients, some
with a history of cancer (the Previous group), and some without (the No-Previous group). We
assume that only the Previous group is subject to the bias, which takes the form of a random lead
time that is added to the latent survival that the patient would have experienced under usual care.
In the No-Previous group, we see the natural survival only, untainted by bias. To model these
variables, we describe the logit of the post–lead-time death hazard by a spline, allowed to differ
between Previous and No-Previous groups, and the lead time as an independent negative
binomial (NB); we denote our model LS/NB, for Logit-Spline/Negative Binomial. These
assumptions give us the means to construct parsimonious models. We apply the method to new
lung cancer diagnoses from a large national database.
1.2 The Lung Cancer Data
We extracted our data from the linked SEER-Medicare database. We included patients 66
years or older with primary lung cancer diagnosed between 2000 and 2011, an interval that
represents the most recent data available and produces a large sample size. All patients had full
coverage of Medicare Parts A and B from 1 year before to 1 year after the lung cancer diagnosis.
We included only patients with either non–small cell (NSCLC) or small cell (SCLC) lung cancer
histology. To ensure complete claims data, we excluded patients who participated in health
maintenance organizations and those with only autopsy or death certificate records. We also
omitted patients with incomplete diagnosis or death dates or discrepancies in SEER and
Medicare birth dates of a year or more.
3

To preserve patient anonymity, SEER-Medicare death and diagnosis data include only the
month and year of these events. Thus, survival is measured as the interval, in integer months,
between the month of diagnosis and the month of death, and the survival times are effectively
discrete. This creates the possibility of survival times of 0 months.
We conducted analyses stratified by the stage of the diagnosed lung cancer, for 2 reasons:
First, survival varies greatly by stage, and thus, the strata represent clinically distinct groups.
Second, symptoms and tumor aggressiveness differ by stage, in that earlier stages are less likely
to be symptomatic and therefore more susceptible to lead-time bias. We classified patients by the
American Joint Committee on Cancer criteria into stages I&II, III, and IV. We combined stages I
and II because they are more similar to each other than to higher stages, and they represent a
relatively small proportion of lung cancer (in our data, stage II is only around 3% of all cases).4
We excluded the heterogeneous “unstaged” stratum.
We used propensity-score matching to reduce confounding from differences in baseline
mortality risk between the Previous and No-Previous groups. We computed a propensity score
predicting previous cancer status from available covariates: age, sex (F, M), race/ethnicity
(white, black, Hispanic, other), marital status (married, separated/divorced/widowed, single,
unknown), histology (SCLC, NSCLC-adenocarcinoma, NSCLC-squamous, NSCLC-other),
Charlson comorbidity score (0, 1, 2+, not available), Medicaid status (Y, N), and lung cancer
treatment (surgery only, chemotherapy only, radiation only, ≥2 treatments, no
surgery/chemo/radiation). As there were fewer patients in the Previous group, we paired a single
Non-Previous patient with each Previous patient by nearest-neighbors matching.
The Institutional Review Board of the University of Texas Southwestern Medical Center
approved our study.
4

1.3 Methods
1.3.1 The LS/NB Model
In the No-Previous group, we take the observed survival time to represent the actual survival
time from clinical diagnosis, which we denote the post–lead-time survival; we label this variable
𝑋𝑁 . In the Previous group, we assume that the observable survival time 𝑍 is the sum of 2
independent, latent components: the lead time 𝑇 and the post–lead-time survival 𝑋𝑃 ; that is, 𝑍 =
𝑇 + 𝑋𝑃 .15 We assume moreover that 𝑋𝑁 , 𝑋𝑃 , and 𝑇 take values in the nonnegative integers. Our
strategy is to assume flexible models for 𝑋𝑁 and 𝑋𝑃 that differ by at most a single parameter.
Because 𝑋𝑁 is fully observed (except for censoring), we can use the hypothesized similarity of
𝑋𝑁 and 𝑋𝑃 as a lever to extract information on the distribution of lead times.
We first consider the distribution of post–lead-time survival in the No-Previous group,
labeled 𝑋𝑁 . We denote the probability mass function of 𝑋𝑁 as 𝑓𝑁 (𝑥) = Pr[𝑋𝑁 = 𝑥], its survival
function as 𝑆𝑁 (𝑥) = Pr[𝑋𝑁 ≥ 𝑥] = ∑∞
𝑗=𝑥 𝑓𝑁 (𝑗), and its hazard function as ℎ𝑁 (𝑥) =
Pr[𝑋𝑁 = 𝑥|𝑋𝑁 ≥ 𝑥] = 𝑓𝑁 (𝑥)⁄𝑆𝑁 (𝑥), for 𝑥 ∈ (0, 1, 2, ⋯ ).
Attempts to model survival with standard discrete and continuous distributions revealed
substantial lack of fit in this large database. A purely nonparametric model was also unsuccessful
(see the discussion below). Thus, there was a need for an intermediate approach — a survival
model that offers reasonable flexibility with a modest number of parameters. Plots of the logit of
the empirical hazard against time revealed that this function is amenable to description with a
linear spline having a modest number of knots.16 Thus, for the No-Previous group, we assume
the logit hazard is of the form

5

𝑚+1

ℎ𝑁 (𝑥)
𝜆𝑁 (𝑥; 𝛽) ≡ 𝑙𝑛
= 𝛽0 + 𝛽1 𝑥 + ∑ 𝛽𝑗 (𝑥 − 𝑘𝑗−1 )+ , 𝑥 ∈ {0, 1, 2, ⋯ },
1 − ℎ𝑁 (𝑥)
𝑗=2

where 0 < 𝑘1 < ⋯ < 𝑘𝑚 are preselected knots and (𝑢)+ = max(0, 𝑢We assume moreover that
the post–lead-time survival in the Previous group differs from that in the No-Previous group
according to a proportional odds model on the hazard function. That is, we take the logit hazard
for the Previous group 𝜆𝑃 (𝑥) to be

𝜆𝑃 (𝑥; 𝛽, 𝛾) ≡ 𝑙𝑛

ℎ𝑃 (𝑥)
= 𝜆𝑁 (𝑥; 𝛽) + 𝛾, 𝛾 ∈ (−∞, ∞).
1 − ℎ𝑃 (𝑥)

The odds ratio (OR) of hazards comparing the Previous group with the No-Previous group is
therefore OR = exp(𝛾).
In computations, we can begin with the logit hazard 𝜆(𝑥) and compute the hazard as ℎ(𝑥) =
1/[1 + exp(−𝜆(𝑥))], the survival function as 𝑆(𝑥) = ∏𝑗<𝑥[1 − ℎ(𝑗)], and the probability mass
function as 𝑓(𝑥) = ℎ(𝑥)𝑆(𝑥).
As indicated above, we take survival 𝑍 in the Previous group to be the sum of a lead time 𝑇
and the post–lead-time survival 𝑋𝑃 . Because 𝑇 is a latent variable, it is convenient to model it
with a low-parameter discrete distribution. We chose the NB, as it has only 2 parameters but can
present unimodal shapes and imposes a less strict functional relationship between mean and
variance than the Poisson. Specifically, we assume that lead time follows the NB distribution
𝑇~NB(𝜌, 𝜎), with probability mass function parameterized as

𝑓𝑇 (𝑡; 𝜌, 𝜎) =

Γ(𝑡 + 𝜌)
𝜎 𝜌 (1 − 𝜎)𝑡 , 𝑡 ∈ (0, 1, 2, ⋯ )
Γ(𝜌)Γ(𝑡 + 1)

for 𝜌 > 0, 0 < 𝜎 ≤ 1. The probability mass function for 𝑍 is the convolution
6

𝑧

𝑓𝑍 (𝑧) = ∑ 𝑓𝑇 (𝑡)𝑓𝑃 (𝑧 − 𝑡) , 𝑧 ∈ (0,1,2, ⋯ ),
𝑡=0

where 𝑓𝑇 (∙) and 𝑓𝑃 (∙) are the probability mass functions of 𝑇and 𝑋𝑃 , respectively.
With this large data set of discrete event times, we can hasten computations by structuring
the data in a frequency table. We categorize data by group (Previous or No-Previous), duration
of survival, and event status (censored or dead), as shown in Table 1-1. The index 𝑥 represents
(𝐴)

the possible survival times and runs from 0 to 𝑀; 𝑛𝑥 represents the number of subjects alive
(𝐴)

going into time 𝑥 in group 𝐴; 𝑑𝑥 represents the numbers of subjects dying at time 𝑥 in group 𝐴;
(𝐴)

(𝐴)

(𝐴)

(𝐴)

and 𝑐𝑥 is the numbers of subjects censored at time 𝑥 in group 𝐴. Thus, 𝑛𝑥 = 𝑛𝑥−1 − 𝑑𝑥−1 −
(𝐴)

𝑐𝑥−1 , 𝑥 = 1, ⋯ , 𝑀. An empirical estimate of the hazard at time 𝑥 in the No-Previous group is the
fraction of deaths among those at risk:
(𝑁)

ℎ̂𝑁 (𝑥) =

𝑑𝑥

(𝑁)

𝑛𝑥

, 𝑥 = 0, ⋯ , 𝑀.

Table 1-1. Tabular representation of the Surveillance, Epidemiology, and End Results–Medicare
lung cancer data
Time
0
1
2
⋮
𝑥
⋮
𝑀

At Risk
(𝑃)
𝑛0
(𝑃)
𝑛1
(𝑃)
𝑛2
⋮
(𝑃)
𝑛𝑥
⋮
(𝑃)
𝑛𝑀

Previous
Died
Censored
(𝑃)
(𝑃)
𝑑0
𝑐0
(𝑃)
(𝑃)
𝑑1
𝑐1
(𝑃)
(𝑃)
𝑑2
𝑐2
⋮
⋮
(𝑃)
(𝑃)
𝑑𝑥
𝑐𝑥
⋮
⋮
(𝑃)
(𝑃)
𝑑𝑀
𝑐𝑀
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No-Previous
At Risk
Died
Censored
(𝑁)
(𝑁)
(𝑁)
𝑛0
𝑑0
𝑐0
(𝑁)
(𝑁)
(𝑁)
𝑛1
𝑑1
𝑐1
(𝑁)
(𝑁)
(𝑁)
𝑛2
𝑑2
𝑐2
⋮
⋮
⋮
(𝑁)
(𝑁)
(𝑁)
𝑛𝑥
𝑑𝑥
𝑐𝑥
⋮
⋮
⋮
(𝑁)
(𝑁)
(𝑁)
𝑛𝑀
𝑑𝑀
𝑐𝑀

1.3.2 Estimation
Denote the probability mass function and survival function at time 𝑥 in the No-Previous
group as 𝑓𝑋 (𝑥; 𝛽) and 𝑆𝑋 (𝑥; 𝛽), respectively. Using our tabular notation, the loglikelihood for 𝛽
in the No-Previous group is
𝑀
(𝑁)

(𝑁)

ln𝐿𝑁 (𝛽) = ∑[𝑑𝑥 ln 𝑓𝑋 (𝑥; 𝛽) + 𝑐𝑥

ln 𝑆𝑋 (𝑥; 𝛽)].

𝑥=0

Similarly, let 𝑓𝑍 (𝑧; 𝛽, 𝛾, 𝜌, 𝜎) and 𝑆𝑍 (𝑧; 𝛽, 𝛾, 𝜌, 𝜎) be the probability mass and survival functions,
respectively, for the Previous group, derived form Equation 1. The loglikelihood contribution for
𝛽, 𝛾 (the log OR for the post-lead-time survival) and 𝜌, 𝜎 (the parameters of the lead-time
distribution) from the Previous group is then
𝑀
(𝑃)

(𝑃)

ln𝐿𝑃 (𝛽, 𝛾, 𝜌, 𝜎) = ∑[𝑑𝑧 ln 𝑓𝑍 (𝑧; 𝛽, 𝛾, 𝜌, 𝜎) + 𝑐𝑧 ln 𝑆𝑍 (𝑧; 𝛽, 𝛾, 𝜌, 𝜎)].
𝑧=0

Combining these expressions, the loglikelihood form the entire data set is
ln𝐿(𝛽, 𝛾, 𝜌, 𝜎) = ln𝐿𝑁 (𝛽) + ln𝐿𝑃 (𝛽, 𝛾, 𝜌, 𝜎).
We obtain the maximum likelihood estimate (MLE) 𝛽̂ , 𝛾̂, 𝜌̂, 𝜎̂ by maximizing Equation 3
numerically using the limited-memory Broyden-Fletcher-Goldfard-Shanno method with box
constraints, a quasi-Newton algorithm implemented in R function optim().17 We estimated the
mean lead time 𝐸(𝑇) as 𝜌̂(1 − 𝜎̂)⁄𝜎̂ and the OR as exp(𝛾̂), and we construct confidence
intervals (CIs) for these parameters by the delta method. R code is available from the first author.
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1.3.3 Sensitivity Analysis
We conducted a set of sensitivity analyses to evaluate robustness of results to key model
assumptions.
The first analysis assessed the effect of varying assumptions about each part of the post-leadtime survival model on the parameters of the other part. We first assumed that there is no lead
time (𝑇 ≡ 0) and estimated the corresponding difference in survival between the Previous and
No-Previous groups (now completely described by the OR). Next, we assumed fixed values of 𝛾
(the log OR for the survival difference) and obtained the corresponding estimates of the
̂
remaining parameters 𝛽, 𝜌,
𝜎(𝛾).
The second analysis assessed robustness to the assumed independence of 𝑋𝑃 and 𝑇. Using
our MLE as the truth, we simulated survival time 𝑋𝑁 in the No-Previous group through its spline
model. For the Previous group, we assumed the MLE marginal distributions and simulated 𝑋𝑃
and 𝑇 from a bivariate normal copula with underlying correlation 𝜃, generating 𝑍 = 𝑋𝑃 + 𝑇.
After simulating data for both groups, we estimated LS/NB assuming independence of lead time
and survival, comparing the estimated mean lead time under the varying assigned correlations.
The third analysis examined the effect of the assumed distribution of lead time 𝑇. In addition
to the NB, we evaluated a range of models including the geometric, Poisson, zero-inflated
Poisson, zero-inflated NB, and a nonparametric (multinomial) distribution that assumes support
on a small number of integers but is otherwise unrestricted. We calculated MLEs of 𝐸(𝑇) and
OR under each model and compared fits via the Akaike information criterion (AIC).
In a final sensitivity analysis, we compared results from the propensity-score-matched
sample with an unmatched analysis that applied the model to the entire data set.
9

1.4 Results
1.4.1 Preliminary Analyses
We identified 215 718 SEER-Medicare lung cancer diagnoses, of whom 22% were stage
I&II, 24% stage III, and 39% stage IV; the remaining 15% were unstaged. Roughly 20% had a
previous cancer (Table 1-2).
We first analyzed the data by computing mean survival (restricted to 160 month), estimating
a proportional hazards model with Previous group status as the sole covariate, and comparing the
groups by a logrank test; results appear in Table 1-3. For lung cancer mortality, mean survival is
greater in the Previous group in each stage, with hazard ratios ranging from 0.82 to 0.78. For allcause mortality, mean survival is shorter in the Previous group in stage I&II (HR = 1.05) but
longer in the higher stages (HR = 0.94 in stage III and HR = 0.90 in stage IV). Kaplan-Meier
survival plots appear in Figure 1-1.
Figure 1-2 displays estimated hazard functions for lung cancer and all-cause death in the NoPrevious group, stratified by lung cancer stage. We computed the “raw” estimates by Equation 2
and the “LS/NB” estimates by fitting the model to the entire matched data set. We placed knots
at𝑘1 = 1, 𝑘2 = 5, 𝑘3 = 50, and 𝑘1 = 100, where visual inspection suggested a possible change
in the slope of the logit hazard. Evidently the model offers a good fit. Table 1-4, which compares
Kaplan-Meier estimates of the survival function with estimates under the spline model for the
No-Previous group, again shows that the model fits well.
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Table 1-2. Surveillance, Epidemiology, and End Results–Medicare data: count of patients by
stage and previous cancer diagnosis
Stage
Original data
I&II
III
IV
Matched data
I&II
III
IV

Previous, %

No-Previous, %

Total

10 187 (22)
8474 (16)
12 716 (15)

36 402 (78)
43 841 (84)
70 852 (85)

46 589
52 315
83 568

10 187 (50)
8473* (50)
12 715* (50)

10 187 (50)
8473 (50)
12 715 (50)

20 374
16 946
25 430

*Omitting subjects who had missing marital status.

Table 1-3. Surveillance, Epidemiology, and End Results–Medicare lung cancer data: summary of
mortality in the matched data
Stage

Previous

I&II
III
IV

90.4
33.8
16.5

I&II
III
IV

52.9
19.1
9.4

Mean Survival in Months*
No-Previous†
HR (95% CI)
Death from lung cancer
83.0
0.82 (0.79-0.86)
26.3
0.80 (0.77-0.83)
10.8
0.78 (0.76-0.80)
Death from any cause
56.4
1.05 (1.02-1.09)
18.1
0.94 (0.91-0.97)
8.1
0.90 (0.88-0.93)

Logrank P
< .0001
< .0001
< .0001
0.0033
< .0001
< .0001

Abbreviations: CI, confidence interval; HR, hazard ratio from a Cox model.
*Restricted mean with upper limit = 160 months
†Reference group

1.4.2 LS/NB Model Estimates
We applied LS/NB to the matched data set, estimating simultaneously the spline coefficients,
OR, and the lead-time parameters. The estimated LS/NB survival curves in Figure 1-3 agree well
with the superimposed Kaplan-Meier curves; the divergence of the empirical and estimated
curves in the right tail partly reflects plotting survival on the log scale, which magnifies
differences at small values, and partly the reduced precision in this range.
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Maximum likelihood estimates of 𝐸(𝑇) and OR appear in the top panel of Table 1-5. For
lung cancer mortality, the estimated 𝐸(𝑇) for patients with stage I&II lung cancer in the Previous
group is 11.3 months; estimated mean lead times in stages III and IV are roughly 1 month and 1
week, respectively. Even allowing for a potential lead-time bias, the ORs are less than 1
(significantly so in stages III and IV); thus, accounting for lead-time bias does not nullify the
beneficial effect of having had a previous cancer on lung cancer mortality. As mean lead time
declines with advancing stage, the effect of surviving a previous cancer increases, with the
greatest survival advantage (OR = 0.79; 95% CI, 0.77-0.82) appearing in stage IV.
For all-cause death (Figure 1-3, right panel; Table 1-5, top right), the estimated mean lead
times are 3.4, 1.1, and 1.1 months for patients in stages I&II, III, and IV, respectively. In stage
I&II, accounting for lead-time bias accentuates an already statistically significant overall survival
advantage for the No-Previous group. For stages III and IV, incorporating lead time in the model
renders the OR indistinguishable from unity. Thus, for all-cause death, the apparent survival
advantage in the Previous group with stages III and IV cancer may well reflect a modest leadtime bias. In stage I&II, the survival advantage in the No-Previous group is larger than the
estimated hazard ratio of 1.05 from the Cox model.
As demonstrated in Figure 1-3 and Table 1-5, the survival advantage of the Previous group is
only apparent when one censors non-lung cancer deaths; for overall survival, the No-Previous
group does slightly better in stage I&II and roughly the same in stages III and IV, even after
accounting for lead time. Figure 1-4, which displays cumulative incidence curves18 of death from
cancer and other causes in stage I&II and stage IV, explains this observation (we omit stage III,
which is similar to stage IV). The curves, unadjusted for lead-time bias, show that subjects in the
Previous group at every stage have a lower rate of death from lung cancer but a higher rate of
12

death from other causes. In stage I&II, the risk of lung cancer death is low in both groups and
similar to the risk of death from other causes; thus, overall death rates slightly favor the NoPrevious group. In stage IV, the risk of lung cancer mortality is the dominant hazard component;
thus, there is a modest advantage for the Previous group in overall mortality, mirroring the
findings in Table 1-3, which also does not account for lead time.
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Figure 1-1. Kaplan-Meier survival curves (on the log scale) for newly diagnosed lung cancer
patients, stratified by stage
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Figure 1-2. Raw (KM) and estimated hazard functions of lung cancer–specific and overall
survival in the No-Previous group, stratified by stage. KM, Kaplan-Meier; LS/NB, LogitSpline/Negative Binomial
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Table 1-4. Estimated lung cancer–specific and all-cause survival in months (%) for the NoPrevious group
Stage
Time
0
1
3
5
40
80
100
120
140

I&II
KM
99.1
97.3
93.7
90.8
59.8
46.4
42.1
39.7
36.2

Lung Cancer-Specific Survival, %
III
IV
LS
KM
LS
KM
99.0
94.4
94.4
91.7
97.2
84.7
85.2
74.9
93.8
71.9
71.5
54.0
90.6
63.5
62.2
42.3
59.7
17.2
16.7
5.0
46.5
10.1
10.1
2.1
42.5
8.6
8.6
1.8
39.2
7.6
7.6
1.2
36.5
7.3
7.0
0.8

LS
91.7
74.8
54.0
42.4
4.8
2.3
1.9
1.5
0.8

I&II
KM
98.4
95.7
90.3
86.3
47.3
28.6
22.7
17.6
13.5

LS
98.4
95.4
90.4
86.3
46.9
28.8
22.7
17.6
13.2

All-Cause Survival, %
III
IV
KM
LS
KM
92.6
92.4
89.3
81.0
81.7
70.1
67.0
66.6
48.0
57.9
56.8
36.2
11.9
11.5
3.2
5.1
5.2
1.0
3.6
3.5
0.8
2.6
2.5
0.4
2.1
1.9
0.2

LS
89.3
70.1
47.9
36.5
3.0
1.1
0.8
0.5
0.2

1.4.3 Sensitivity Analyses
Our initial sensitivity analysis estimated the OR assuming no lead time (𝑇 ≡ 0) and
estimated 𝐸[𝑇] while holding OR fixed at a range of likely values. Results appear in Table 1-6.
For lung cancer death, with no lead-time bias, the estimated OR is 0.82, 0.80, and 0.77 for stages
I&II, III, and IV, respectively (note the similarity to the hazard ratios in Table 1-3). As we allow
the OR to increase to 1.2, the mean lead time rises to as high as 44 months for stage I&II and 7.7
months for stage IV (Table 1-6 and Figure 1-5). This is to be expected, because the larger the
OR, the greater must be the lead-time bias to compensate for it. If the entire lung cancer survival
difference is explained by lead time, that is, if OR = 1, then the mean lead time is estimated to be
15.4, 8.5, and 5.1 months for stages I&II, III, and IV, respectively. Thus, a substantial mean lead
time—more than 1 year in stage I&II — is needed to nullify any apparent positive effect of
previous cancer on lung cancer survival. For all-cause death with no lead time, we estimate the
OR to be 1.05, 0.94, and 0.90 for stages I&II, III, and IV, respectively. The estimated 𝐸[𝑇] also
increases as OR increases (Figure 1-5, right panel) but less dramatically than when lung cancerspecific death is the end point. A recurring theme of the analysis is that 𝐸̂ [𝑇] declines as the
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stage increases. This is reasonable, as we expect higher-stage tumors to progress more rapidly
from being just detectable to manifesting clinical signs and symptoms.
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Figure 1-3. Estimated survival functions (on the log scale) by Kaplan-Meier (KM) and the LogitSpline/Negative Binomial (LS/NB) method, stratified by stage
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The second analysis evaluated sensitivity to the assumed independence between 𝑇 and 𝑋𝑃 by
simulating data with marginal distributions similar to those in our lung cancer death data but
with correlation of 𝑇 and 𝑋𝑃 induced by a normal copula. Results appear in Figure 1-6. With data
generated under independence, 𝐸̂ [𝑇] is 9.97 (95% CI, 7.00-12.94), 1.22 (95% CI, 0.80-1.63), and
0.40 (95% CI, 0.15-0.65) months for stages I&II, III, and IV, respectively. Failure to account for
correlation induces a negative bias when the correlation is positive and vice versa. The trend is
most evident in stage I&II, where lead time is longest. Because positive correlation of 𝑇 and 𝑋𝑃
is the more plausible alternative to independence, a faulty assumption of independence will
likely lead to underestimation of 𝐸[𝑇]. Xu et al observed a similar tendency in a nonparametric
model of breast screening.19 For stage I&II, 𝐸̂ [𝑇] lies in the 95% CI (red dash-dotted line) under
independence if the correlation is in the range (-0.2, 0.1). For stage IV, even if the correlation is
as large as 0.4, 𝐸̂ [𝑇] is still within the 95% CI under independence. Thus, an incorrect
assumption of independence can affect results, most likely leading to a negative bias, but the
correlation must be substantial for this to occur. One can avoid this bias by conditioning on
factors that confound the relationship between 𝑋𝑃 and 𝑇. One can also attempt to model the
correlation, but as only the sum of 𝑇 and 𝑋𝑃 is ever observed, it seems unlikely that it will be
possible to estimate such a model robustly.
Third, we evaluated sensitivity to the assumed lead-time distribution by estimating
parameters under a range of models for 𝑇: NB, geometric, Poisson, zero-inflated Poisson, zeroinflated NB, and a nonparametric distribution with mass at (0, 1, ⋯ , 15) for stage I&II or
̂ , the
(0, 1, ⋯ , 5) for stage III and stage IV. In Table 1-7, we present for each model 𝐸̂ [𝑇], OR
first few values of the probability mass function of 𝑇, and the AIC. Among the parametric
distributions, the geometric, Poisson, and zero-inflated Poisson never fit well; they give larger
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AIC and usually underestimate both 𝐸[𝑇] and OR. Zero-inflated NB gives results similar to NB,
although the latter has lower AIC. All estimated mass functions assign highest probability to 𝑇 =
0; evidently, the important difference is that NB permits a longer tail and therefore a potentially
higher mean. The mean lead time is sensitive to model assumptions, the OR less so. Thus, it
appears that NB is a satisfactory model for reasons of flexibility and parsimony, although users
must anticipate some sensitivity in the estimated𝐸[𝑇].
Finally, we estimated the model on the entire data set; see the bottom panel of Table 1-5.
Compared with the matched analysis, estimates of OR change by no more than about 1%.
Estimates of 𝐸[𝑇] are less robust, possibly changing by up to a half-month but never leading to a
qualitative difference in interpretation. Confidence intervals are narrower thanks to the larger
sample size.

Table 1-5. Estimated mean lead time E[T] (month) and OR, by cause of death and stage
Stage
I&II
III
IV
I&II
III
IV

Lung Cancer-Specific Mortality
̂
̂ (95% CI)
𝐸 [𝑇] (95% CI)
OR
Matched sample
11.3 (3.8-33.3)
0.96 (0.86-1.08)
1.1 (0.5-1.7)
0.85 (0.82-0.88)
0.3 (0.02-0.5)
0.79 (0.77-0.82)
Unmatched sample
11.2 (2.4-20.1)
0.96 (0.89-1.05)
0.7 (0.2-1.1)
0.84 (0.82-0.86)
0.4 (0.2-0.6)
0.80 (0.78-0.82)
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All-cause Mortality
̂
̂ (95% CI)
𝐸 [𝑇] (95% CI)
OR
3.4 (1.1-5.8)
1.1 (0.5-1.7)
1.1 (0.4-1.7)

1.14 (1.08-1.21)
1.00 (0.96-1.03)
1.00 (0.96-1.04)

3.5 (1.9-5.1)
0.9 (0.2-1.6)
0.9 (0.3-1.5)

1.14 (1.10-1.18)
1.00 (0.96-1.04)
0.99 (0.94-1.05)

Figure 1-4. Cumulative incidence curves for stage I&II and stage IV (stage III is similar to stage
IV)

Table 1-6. Sensitivity analysis of estimates of OR (assuming 𝑇 ≡ 0) and mean lead time 𝐸(𝑇)
(for fixed OR)
Stage
I&II

III

IV

Lung Cancer Mortality
OR (SE)
𝐸̂ [𝑇] (SE)
0.82 (0.013)
0
0.90
5.0 (1.1)
1.00
15.4 (2.6)
1.10
28.6 (3.2)
1.20
44.4 (3.2)
0.80 (0.011)
0
0.90
2.2 (0.5)
1.00
8.5 (1.2)
1.10
14.4 (1.4)
1.20
18.8 (1.4)
0.77 (0.0082)
0
0.80
0.3 (0.1)
0.90
2.9 (0.4)
1.00
5.1 (0.4)
1.10
6.6 (0.4)
1.20
7.7 (0.4)

All-Cause Mortality
OR (SE)
𝐸̂ [𝑇] (SE)
1.05 (0.013)
0
----1.10
2.4 (0.4)
1.20
5.9 (0.8)
0.94 (0.011)
0
--1.00
1.1 (0.2)
1.10
3.2 (0.4)
1.20
5.5 (0.4)
0.90 (0.0087)
0
----1.00
1.1 (0.1)
1.10
2.1 (0.1)
1.20
3.0 ()0.1

Abbreviations: OR, odds ratio; SE, standard error. Figures in italic are fixed in the sensitivity analysis.
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Figure 1-5. Estimated mean lead time (in month) as a function of odds ratio (OR), by stage

Figure 1-6. Analysis of sensitivity of 𝐸̂ [𝑇] (in months) to assumed independence of 𝑇 and 𝑋𝑃
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Table 1-7. Sensitivity to the assumed lead-time distribution
Stage
I&II

Parameter
NB
Geometric
Poisson
ZIP
ZINB
NP
11.3
1.42
0.35
0.40
8.39
2.24
𝐸̂ [𝑇]
̂
0.96
0.84
0.82
0.82
0.94
0.87
OR
0.640
0.704
0.704
0.712
0.677
0.741
Pr[𝑇 = 0]
0.059
0.208
0.247
0.195
0.053
0.043
Pr[𝑇 = 1]
0.032
0.062
0.043
0.071
0.029
0.023
Pr[𝑇 = 2]
0.022
0.018
0.0051
0.017
0.020
0.016
Pr[𝑇 = 3]
0.017
0.0054
4.4e-4
0.0031
0.016
0.012
Pr[𝑇 = 4]
0.014
0.0016
3.1e-5
4.6e-4
0.013
0.010
Pr[𝑇 = 5]
AIC
85142.4
85159.0
85160.0
85161.3
85143.8
85175.7
III
1.11
1.02
0.0064
0.019
0.83
0.57
𝐸̂ [𝑇]
̂
0.85
0.80
0.80
0.80
0.63
0.83
OR
0.828
0.983
0.994
0.981
0.860
0.829
Pr[𝑇 = 0]
0.051
0.016
0.0063
0.018
0.047
0.048
Pr[𝑇 = 1]
0.026
2.7e-4
2.0e-5
3.3e-4
0.024
0.025
Pr[𝑇 = 2]
0.017
4.4e-6
4.2e-8
3.8e-6
0.015
0.0062
Pr[𝑇 = 3]
0.012
7.2e-8
6.7e-11
3.4e-8
0.010
0.0046
Pr[𝑇 = 4]
0.0092
1.2e-9
8.6e-14
2.4e-10
0.0078
0.087
Pr[𝑇 = 5]
AIC
94836.9
94851.2
94850.7
94853.5
94839.8
94834.8
IV
0.28
1.02
0.013
0.011
0.25
0.20
𝐸̂ [𝑇]
̂
0.79
0.77
0.77
0.77
0.79
0.79
OR
0.925
0.984
0.986
0.989
0.927
0.924
Pr[𝑇 = 0]
0.029
0.016
0.013
0.011
0.030
0.029
Pr[𝑇 = 1]
0.013
2.6e-4
9.0e-5
8.5e-5
0.014
0.013
Pr[𝑇 = 2]
0.0081
4.3e-6
4.0e-7
4.5e-7
0.0081
0.0082
Pr[𝑇 = 3]
0.0054
7.1e-8
1.4e-9
1.8e-9
0.0054
0.0055
Pr[𝑇 = 4]
0.0039
1.2e-9
3.7e-12
1.8e-9
0.0038
0.019
Pr[𝑇 = 5]
AIC
128990.1
128993.7
128993.7
128995.6
128992.0
128993.5
Abbreviations: AIC, Akaike information criterion; NB, negative binomial; NP, nonparametric with support at
(0,1,…,15) for stage I&II or (0,1,…,5) for stage III and stage IV; ZINB, zero-inflated NB; ZIP, zero-inflated
Poisson.
Underlined value is the smallest for models in that stratum.

1.5 Discussion
1.5.1 Summary and Context
Our proposed LS/NB model allows estimation of the mean lead time in cancer patients who
have a previous diagnosis of another cancer. Applying it to SEER-Medicare data with lung
cancer–specific survival as the outcome, estimated mean lead times are roughly 11 months for
stage I&II lung cancer and around 1 month or less for higher stages. For death from any cause,
the estimated mean lead times are roughly 3 months for stage I&II and 1 month for higher stages.
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Even after accounting for lead time, the Previous group has a lower lung cancer mortality hazard
in all stages, statistically significantly so in stages III and IV. For all-cause mortality, accounting
for lead time leaves survival slightly worse in the Previous group for stage I&II and practically
equal to No-Previous survival in more advanced stages.
Most discussion of lead-time bias assumes a context of cancer screening; to our knowledge,
this is the first analysis of lead time as it may arise from idiosyncratically enhanced surveillance
in cancer survivors. Walter and Stitt proposed modeling the survival of screen-detected cases by
the hazard function; their analysis requires specification of the duration of the detectable
preclinical phase and assumptions of independent, exponential distributions for the lead time and
the total survival time after diagnosis.15 Xu and Prorok assumed that the lead time is exponential
but used a nonparametric method to estimate post–lead-time survival.20 Duffy et al assumed an
exponential distribution of the lead time, adjusting the survival times of the screen-detected cases
by subtracting an estimated conditional mean lead time.21
1.5.2 Modeling Issues
The LS/NB model departs from common practice in taking survival times to be discrete. This
approach does not primarily reflect an impulse to model the data as they are, although SEERMedicare survival times are in fact rounded to the nearest month. With the wide range of
survival times, this is actually a fine rounding grid, and analyzing the data as though they are
continuous should cause little bias.22 An advantage of assuming discreteness is that it simplifies
calculation, as one can compute all needed quantities — probabilities, means, and likelihood
terms — by direct summation.
Because standard discrete distributions fit poorly to post-lead-time survival, we eschewed
them in favor of flexible, easily estimated spline models on the logit hazard. Modeling survival
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time in the Previous group is more challenging, because if one specifies both the lead time and
the post–lead-time survival using nonparametric or overly flexible parametric forms, their
convolution can be nonidentifiable. Therefore, for the lead-time distribution, we settled on the 2parameter NB, which is more flexible than the Poisson and geometric distributions but retains an
easily computed mean function. Analysis under a range of alternative models showed substantial
sensitivity of estimates of 𝐸(𝑇) and modest sensitivity of estimates of OR. Supporting our initial
intuition, the NB appeared to offer a good fit when evaluated by the AIC.
Our analysis is made possible by the availability of the No-Previous group — that is, a
sample whose survival times are free of lead-time bias. Assuming that survival in the NoPrevious group is the same as post–lead-time survival in the Previous group, possibly up to an
OR parameter, we can readily identify the lead-time distribution. An approach that we tried
initially was to estimate a common 𝑆𝑁 (𝑥) = 𝑆𝑃 (𝑥) nonparametrically from the No-Previous data
and solve for 𝑓𝑇 (𝑡) by inverting the convolution equations (1). Unfortunately, the solution
yielded probabilities outside [0, 1], even when we constrained the support of 𝑇 to include only
the first few nonnegative integers. Thus, despite the large sample size, some smoothing is
necessary.
A key assumption is that 𝑇 and 𝑋𝑃 are independent. A plausible departure from this
assumption is that the association is positive, in which case tumors that arise with shorter lead
time are also more rapidly fatal.19 As both lead time and post–lead-time survival in the Previous
group are latent, one cannot test this hypothesis robustly. In a sensitivity analysis, we
demonstrated that failure to account for correlation could induce bias when the true correlation is
moderate. One could reduce this bias by adjusting for potential confounders of the relationship
between lead time and post–lead-time survival.
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We considered correction methods like those proposed by Duffy et al21 but found them to
have several shortcomings: First, the adjustments to the observed 𝑧 values use only information
on an assumed exponential distribution of 𝑇 and ignore the model for 𝑋𝑃 ; that is, they adjust
using the incorrect conditioning set 𝑇 ≤ 𝑧 rather than 𝑇 + 𝑋𝑃 ≤ 𝑧. Second, the method requires
that one possess estimates of the parameters of 𝑇 from previous data; such estimates may be
available in special cases, but in general, they are elusive. And finally, even if one could perform
the adjustments correctly by subtracting the conditional mean of 𝑇, the method would be
analogous to single imputation of the predicted mean lead time and therefore would understate
uncertainty. Our attempts to implement these analyses (not shown) demonstrated that adjustment
formulas do not work as well as full estimation within the models from which they are derived.
A multiple-imputation approach that involves taking repeated draws from the predictive
distribution of the latent 𝑋𝑃 given (𝑧, 𝑑) would address this concern.23
As indicated above, the survival advantage of the Previous group is only apparent for deaths
from lung cancer, in an analysis that censors subjects at the time of death from other causes.
Such an analysis implicitly assumes independence of times to death from cancer and other
causes, a hypothesis whose validity is by no means certain and that one cannot test robustly.
Moreover, because SEER cause-of-death data are not adjudicated, this outcome is subject to
errors of misclassification. A possible enhancement of the method would be to jointly model lead
time, mortality from cancer, and mortality from other causes, thereby creating valid estimates of
cause-specific hazard functions.
Assuming that the Previous and No-Previous survival curves are identical except for a leadtime bias, one can estimate 𝐸[𝑇] by simply taking the difference between estimates of 𝐸[𝑍] and
𝐸[𝑋𝑁 ], the first 2 columns in Table 1-3. Estimates computed in this way are similar to the model26

based estimates from the sensitivity analysis with OR = 1.0 in Table 1-6, at least for stages III
and IV. The fact that estimates of 𝐸[𝑇] vary by end point suggests an inadequacy in the model,
because the putative lead-time bias should be identical for survival end points measured from the
same diagnosis time. Jointly modeling the 2 types of death would resolve this ambiguity.
1.5.3 Clinical Implications
Because the SEER-Medicare database contains only persons who are eligible for Medicare,
we restricted our analysis to subjects aged 66 or older; thus, our findings may not be relevant to
the entire lung cancer population. We note, however, that the median age at diagnosis of lung
cancer is 70, and 69% of US lung cancer diagnoses occur at ages >65;24 therefore, our data
represent the majority of US lung cancer patients. Moreover, we recently demonstrated that,
among lung cancer patients in SEER (2009-2013), 8.6% of those <65 years and 18.7% of those
≥65 years are survivors of a previous, non–lung cancer.25 Thus, our study, while limited to older
adults, represents the majority of all lung cancer patients and of lung cancer patients who have
survived a previous cancer.
Our findings suggest that lead-time bias is one possible cause of the observed, modest,
positive effect of a previous cancer diagnosis on lung cancer survival time. Other factors that
underlie the observed differences are unknown but may include physiologic and health care
delivery effects, misclassification, and residual confounding. Because SEER does not conduct
active follow-up, it cannot provide validated data about metastatic disease occurring after initial
cancer diagnosis. Nor does SEER measure smoking status, which is a potentially powerful
confounder. Further studies with prospective, comprehensive data collection would help resolve
these questions.
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The University of Texas Southwestern Medical Center Moncrief Cancer Institute has
established a survivorship program to enhance the quality of life for cancer survivors, focusing
on their mental and physical health. The program includes specialized exercise and nutrition
training, as well as group and individual education and counseling. Benefits of participation in
this program are unknown. We combined tumor registry and electronic medical record data for
the safety-net healthcare system in Tarrant County, TX with participation data from the
survivorship program. We identified patterns of participation through statistical clustering. We
used regression models to measure the effect of participation on behaviors and on the frequency
of Emergency Department (ED) visits. Among 467 program participants, we identified four
clusters representing distinct patterns of participation. Our results demonstrated that participation
in the survivorship program was associated with a 37% lower rate of ED visits (p < 0.0001). The
study findings could further shape delivery of the survivorship services in our institution and
similarly situated organizations across the country. In addition, these findings will provide
insurers and policy makers with information to make evidence-based decisions regarding
reimbursement for cancer survivorship programs.
2.1

Introduction
Cancer detection and treatment advances have led to rapid growth in the number of cancer

survivors. An estimated 15.5 million survivors represented 4.8% of the United States population
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in 2016 and projected to increase by 31% to 20.3 million by 2026.26 Data from the Surveillance,
Epidemiology, and End Results (SEER) Program27 suggest about 67% of people diagnosed with
cancer survive 5 years or more. Although cancer is more survivable than ever, many survivors
become “lost in transition” once systematic care and treatment is finished.28 In addition,
survivors often face devastating physical, psychosocial, and economic effects from the disease
and treatment that affects quality of life. Thus, it has been proposed comprehensive survivorship
programs can help cancer survivors address the likely physical, psychological, social and
financial problems encountered in their next stage of life.29
A major barrier to survivorship care is cost.30 The majority of cancer survivorship programs
are associated with large cancer centers or academic medical centers and limited in scope
because they are expensive and poorly reimbursed. Cancer survivors typically face the high
treatment costs, lost work time and/or impairment in the ability to work31, and loss of health
insurance. As a results, many are unable to afford the additional, unreimburseable costs for
cancer survivorship services.
Moncrief Cancer Institute (MCI), an affiliate of UT Southwestern Medical Center (UTSW),
is a non-profit community-based cancer prevention and support center. MCI has established a
survivorship program using a community-based model to provide patient-centered care. This
survivorship program provides opportunity for cancer survivors to improve their health and
quality of life by addressing any lingering medical and psychosocial effects of illness in addition
to promoting healthy lifestyle changes. MCI offers cancer survivors multidisciplinary services
regardless of diagnosis, stage, treatment provider, socioeconomic status, or insurance coverage.
In this paper, we analyze sociodemographic and clinical characteristics of cancer survivors
who took part in the MCI program. We use statistical clustering methods to identify common
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patterns of service utilization. We further estimate the association of program participation with
frequency of emergency department (ED) visits, to understand the potential impact of
survivorship programs at the health system level.
2.2

Materials and Methods
Study procedures
This retrospective analysis uses three data sources: The John Peter Smith Hospital (JPS)

tumor registry database, JPS healthcare system electronic medical records (JPS EMR), and the
UTSW-MCI Surviviorship database. JPS is a safety-net healthcare system providing care for
low-income, under- and un-insured patients living in Tarrant County, TX. Subjects were patients
18 years and older and diagnosed with cancer between January 1, 2005 and December 31, 2015,
identified from the JPS tumor registry. We divided patients into two groups: The intervention
group are participants who had one or more visits to the UTSW-MCI survivorship program from
November 1, 2012 through December 31, 2016. The control group consisted of patients who did
not participate in the cancer survivorship program during that period.
After the groups were identified, a patient level database was created that contained: 1)
patient sex, age, race/ethnicity, language, marital status, alcohol use, tobacco use, cancer case
class, cancer type, cancer stage, cancer grade, cancer diagnosis year from the tumor registry, 2)
ED visits from the EMR and 3) survivorship program services from the MCI delivery database.
The survivorship program offered eleven different types of program services as follows:
RN Encounter - An Oncology Certified Nurse (OCN) conducts a physical needs
assessment based on cancer treatment and health history, including cancer screening and
surveillance adherence, creating a survivorship care plan where appropriate.
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SW Encounter - A licensed medical social worker (LMSW), completes a psycho-social
evaluation to determine need for care coordination and/or financial assistance.
1:1 Exercise session - An American College of Sports Medicine (ACSM) certified
Cancer Exercise Trainer designs an individualized safe physical post-treatment activity
plan for the participant after reviewing the medical history, exercise history, and fitness
goals. The routine provides guidelines for improvement in areas like cardiovascular
endurance, muscle strength and endurance, flexibility, range of motion, and balance.
Nutrition Counseling – A registered dietitian (RD) evaluates the participants’ dietary
behaviors and needs to provide assistance with making nutritious foods and lifestyles
choices, particularly when food security is an issue.
Midlevel Provider Encounter - Medical consultations provided by a Physician Assistant
for the treatment of comorbid conditions, interval testing post treatment, etc.
Psychology Encounter - A psychologist consults with participants and their families to
address psychosocial distress, anxiety and depression.
Genetic Counseling - A board certified genetic counselor (CGC) assesses the
participant’s family and personal history along with any screening results, to identify the
risk level for cancer and provides genetic testing where appropriate, along with guidance
for early detection and prevention measures.
Group Exercise Session - A safe physical activity designed and coordinated for a group
setting by an ACSM certified Cancer Exercise Trainer.
Support Group Session - Groups led by a licensed medical social worker (LMSW) to
provide counseling for specific issues (e.g. smoking cessation, caregiving) or cancer type
(prostate, brain, head-and-neck).
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Group Education – RD - A RD provides instruction on healthy food preparation and meal
planning in a group setting.
Group Education – RN – Diagnosis specific education and survivorship care planning
provided in a group setting by an OCN.
Each service was designed to help cancer survivors to develop a healthy lifestyle, reduce the risk
of recurrence or secondary cancers, and address psychological and social problems as a result of
their disease and its treatment. All participants were strongly encouraged to attend 1 RN and 1
SW visit; after which, they were encouraged to engage in program services aligning with the
needs identified during the initial encounters.
Statistical analysis
We first compared patient characteristics of program participants to all possible nonparticipants and to the matched set of non-participant controls using descriptive statistics
(number, percent) and chi-square statistics from univariate logistic model.
For each type of program service, we estimated a random-effects, zero-inflated Poisson
(ZIP) mixed model to predict the count of visits to that type of program service (Model 1). We
had 11 models separately for 11 type of services and for each participant, 11 random effects were
estimated correspondingly. We then applied principal component analysis (PCA) to the
standardized (subtracted by mean and divided by standard deviation) estimated random effects
from ZIP models. We used the selected components obtained from PCA methods as input to a kmeans clustering algorithm32 that identified distinct clusters in program utilization.
𝑤𝑗 + (1 − 𝑤𝑗 )𝑒 −𝜇𝑖𝑗 𝑦𝑖𝑗 = 0
𝑃𝑟(𝑦𝑖𝑗 ) =

𝑒 −𝜇𝑖𝑗 𝜇𝑖𝑗 𝑦𝑖𝑗
(1 − 𝑤𝑗 )
𝑦𝑖𝑗 > 0
𝑦𝑖𝑗 !
{

Model1
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ln(𝜇𝑖𝑗 ) = 𝛼𝑗 + 𝑒𝑖𝑗 + ln(𝑡𝑖𝑗 )
where = 1, 2, … , 𝑛 : participant ID;
𝑗 = 1, 2, … , 11 : service type indicator;
𝑦𝑖𝑗 : the number of visits of participant 𝑖 to service 𝑗;
𝑤𝑗 : the zero-inflation proportion for service 𝑗;
𝜇𝑖𝑗 : mean number of program visits;
𝛼𝑗 : an intercept parameter;
𝑒𝑖𝑗 : the random individual effect for participant i on type j service;
𝑡𝑖𝑗 : the offset representing the duration between the individual’s starting date of type 𝑗
service and last observed program date of any type of service. Individual’s starting date is
defined as follows: if individual 𝑖 participated in type 𝑗 service, his starting date is either his
enrollment date or the very first observed program date of type 𝑗 service among all participants
(overall first program date of type 𝑗 service ), whichever comes later; if individual 𝑖 didn’t
participate in type 𝑗 service, his starting date is his enrollment data if his last observed program
date is before overall first program date of type 𝑗 service, otherwise his starting date is either his
enrollment data or the overall first program date of type 𝑗 service, whichever comes later.
To study the effect of sociodemographic and clinical factors on program participation, we
fitted a multivariate logistic regression model that estimated the expected probability of
participation, with all measured covariates. Given the considerable number of missing
observations for alcohol use and tobacco use, we imputed missing values using logistic
regression. To do so, we built a logistic regression with observed alcohol use as outcome and all
other covariates except tobacco use as predictors. This model was then used to predict the
missing alcohol use. A similar method was used to impute tobacco use. Because patients can
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have more than one primary reportable neoplasm over their lifetime, we describe characteristics
of the patients’ most recent cancer. Sequence number reflects whether the selected tumor was the
patient’s first or only tumor, or a second or higher-order tumor.33 Case class identifies the role of
the reporting facility in the patient's diagnosis and treatment. Analytical cases are those
diagnosed by or receiving part or all of the first course of treatment at the reporting facility; nonanalytical cases were diagnosed and received all of the first course of treatment at another
facility.34 We used these propensity scores to match each program participant to 3 nonparticipants, allowing us to estimate effects of program participation with minimal confounding
bias.
To study the effect of program participation on frequency of ED visits, we also applied the
random-effects ZIP model to the dataset. We estimated two models. For the first (Model 2), we
examined whether the count of ED visits differed by any program participation. We applied the
model to the propensity score matched data, with count of ED visits as the outcome and
participation status as the predictor. The participation status is always 0 for non-participants; for
a participant, the status switches from 0 to 1 at the time of first participation in a program
service. In this model, the participation status could affect whether the survivors has ED visits
and also the rates of their ED visits if they had any.
𝑤 + (1 − 𝑤)𝑒 −𝜇𝑖 𝑦𝑖 = 0
𝑃𝑟(𝑦𝑖 ) =

Model2
𝑒 −𝜇𝑖 𝜇𝑖 𝑦𝑖
(1 − 𝑤)
𝑦𝑖 > 0
{
𝑦𝑖 !

ln(𝜇𝑖 ) = 𝛼1 + 𝛽1 𝑋𝑖 + 𝑒𝑖 + ln(𝑡𝑖 )
ln (

𝑤
) = 𝛼2 + 𝛽2 𝑋𝑖
1−𝑤

where 𝑖 = 1, 2, ⋯ , 𝑛 : patient ID;
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𝑦𝑖 : the number of ED visits of patient 𝑖;
𝑤 : the zero-inflation proportion;
𝜇𝑖 : mean number of ED visits;
𝛼1 : the intercept parameter to predict the mean number of ED visits;
𝛽1 : the fixed participation effect to predict the mean number of ED visits;
𝑋𝑖 : the participation status ̶ Participants before-program and non-participants: 0;
participants after-program: 1;
𝑒𝑖 : the random individual effect;
𝑡𝑖 : the offset: for non-participants, the offset is the duration between the first and last
recorded ED visit dates; for participants, there are two stages: before-program and after-program.
In the before-program stage, the patients have not yet initiated participation in the survivorship
program; the offset for this stage is the duration between the first ED visit date and the first
survivorship program date. In the after-program stage, the patients have started participating the
program; the offset is the duration between the first program date and the last observed date,
either the last program participation date or the last ED visit date, whichever comes later;
𝛼2 : the intercept parameter to predict the zero-inflation proportion;
𝛽2 : the fixed participation effect to predict the zero-inflation proportion.

For the second model (Model 3), we further examined the program effect on ED utilization
by membership in the program participation clusters. We applied this model only to survivorship
program participants. It took outcome as the count of ED visits and an indicator of cluster
membership as predictor, where each patient was classified into one cluster.
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𝑤 + (1 − 𝑤)𝑒 −𝜇𝑖 𝑦𝑖 = 0
𝑃𝑟(𝑦𝑖 ) =
{

(1 − 𝑤)

Model3
𝑒 −𝜇𝑖 𝜇𝑖 𝑦𝑖
𝑦𝑖 > 0
𝑦𝑖 !

ln(𝜇𝑖 ) = 𝛼 + 𝛽1 𝑋𝑖1 + 𝛽2 𝑋𝑖2 + 𝛽3 𝑋𝑖3 + 𝛽4 𝑋𝑖4 + 𝑒𝑖 + ln(𝑡𝑖 )
where = 1, 2, ⋯ , 𝑛 : participant ID;
𝑦𝑖 : the number of ED visits of participant 𝑖;
𝑤 : the zero-inflation proportion;
𝜇𝑖 : the mean number of ED visits;
𝛼: the intercept parameter to predict the mean number of ED visits;
𝛽1 , 𝛽2 , 𝛽3 , 𝛽4 : the fixed effects of cluster 1-4 to predict the mean number of ED visits;
𝑋𝑖1 , 𝑋𝑖2 , 𝑋𝑖3 , 𝑋𝑖4 : the cluster status indicator; 𝑋𝑖𝑗 = 1, if participants is in cluster𝑗 ;
otherwise, 𝑋𝑖𝑗 = 0, 𝑗 = 1, 2, 3, 4.
𝑒𝑖 : the random individual effect;
𝑡𝑖 : before-program: the offset is the duration between the first ED visit date and the first
survivorship program date; after-program: the offset is the duration between the first program
date and the last observed date, either the last program participation date or the last ED visit date,
whichever comes later.
2.3

Results
Among 8,435 cancer survivors, 467 (5.5%) participated in the survivorship program. The

average age (interquartile range, IQR) is 51.9 (47-59) for participants and 54.8 (47-63) for nonparticipants, additional characteristics by participation status are in Table 2-1. Cancer survivors
who are female, younger, Hispanic or black, have quit smoking, and those with certain cancer
types are significantly more likely to participate in the survivorship program (Table 2-1). We
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then matched each participant to three non-participants based on the propensity score obtained
from the multivariate logistic regression model. The matching balanced the covariates between
the participation groups (p > 0.05 for all covariates after matching). All remaining analyses
compared participants to matched non-participants.
Table 2-1. Summary statistics of participants and non-participants
Covariates

Categories

Total
Sex
Age

Race

Language

Marital
Status

Alcohol

Tobacco

Sequence
number

Participants

Nonparticipants

Matched
Nonparticipants

467

7968

1401

Female

331(70.9)

4296(53.9)

976(69.7)

Male

136(29.1)

3672(46.1)

425(30.3)

18-39

55(11.8)

996(12.5)

177(12.6)

40-54

213(45.6)

2576(32.3)

593(42.3)

55-64

167(35.8)

2887(36.2)

525(37.5)

65+

32(6.8)

1509(18.9)

106(7.6)

Hispanic

171(36.6)

1794(22.5)

498(35.5)

Non-Hisp White

134(28.7)

3740(46.9)

406(29.0)

Non-Hisp Black

149(31.9)

1962(24.6)

456(32.5)

Non-Hisp Other

13(2.8)

472(5.9)

41(2.9)

English

6663(83.6)

1085(77.4)

358(76.6)

Spanish

97(20.8)

916(11.5)

277(19.8)

Other

12(2.6)

389(4.9)

39(2.8)

Single

2959(37.1)

499(35.6)

167(35.8)

Married

174(37.2)

2818(35.4)

530(37.8)

Separated

22(4.7)

213(2.7)

63(4.5)

Divorced

71(15.2)

1166(14.6)

224(16.0)

Widow

24(5.1)

587(7.4)

66(4.7)

Unknown

9(1.9)

225(2.8)

19(1.4)

Current

89(19.0)

1875(23.5)

272(19.4)

Previous

9(1.9)

504(6.3)

27(1.9)

Never

369(79.0)

5589(70.1)

1102(78.6)

Current

115(24.6)

2928(36.7)

351(25.0)

Previous

80(17.1)

1470(18.4)

256(18.3)

Never

272(58.2)

3570(44.8)

794(56.7)

First or only cancer

429(91.9)

6815(85.5)

1275(91.0)

Second or higher order
cancer

38(8.1)

1153(14.5)

126(9.0)
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P value*
before
matchinga

P value*
after
matchingb

<0.001

0.62

<0.001

0.66

<0.001

0.98

<0.001

0.88

0.044

0.95

<0.001

0.99

<0.001

0.81

<0.001

0.57

Case class
Cancer type

Stage

Grade

Analytic

417(89.3)

6615(83.0)

1246(88.9)

Non-analytic

50(10.7)

1353(17.0)

155(11.1)

Breast

143(30.6)

970(12.2)

401(28.6)

Colon and Rectum

42(9.0)

759(9.5)

122(8.7)

Corpus and Uterus

29(6.2)

253(3.2)

90(6.4)

Kidney and Renal

24(5.1)

301(3.8)

73(5.2)

Leukemia

10(2.1)

95(1.2)

29(2.1)

Liver

10(2.1)

326(4.1)

28(2.0)

Lung and Bronchus

28(6.0)

994(12.5)

87(6.2)

Lymphoma-NHL

20(4.3)

208(2.6)

62(4.4)

Myeloma

11(2.4)

119(1.5)

31(2.2)

Oral Cavity Pharynx

10(2.1)

343(4.3)

32(2.3)

Prostate

30(6.4)

376(4.7)

106(7.6)

Vagina, Vulva, Ovary

14(3.0)

222(2.8)

40(2.8)

Other

96(20.6)

3002(37.7)

300(21.4)

In situ

31(6.6)

481(6.0)

91(6.5)

Localized

167(35.8)

2315(29.0)

525(37.5)

Regional

135(28.9)

1684(21.1)

392(28.0)

Distant

93(19.9)

2144(26.9)

277(19.8)

Other

41(8.8)

1344(16.9)

116(8.3)

Poor

101(21.6)

1265(15.9)

298(21.3)

Moderate

137(29.3)

1775(22.3)

409(29.2)

Well

60(12.8)

731(9.2)

192(13.7)

Other

169(36.2)

4197(52.7)

502(35.8)

<0.001

0.83

<0.001

1.0

<0.001

0.97

<0.001

0.97

Cancer
Continuous
<0.001
0.85
Diagnosis
Year
* Two-sided P value calculated from univariate logistic model by Wald Chi-squared test; aComparing participants
to all non-participants; bComparing participants to nonparticipants (1:3) matched on propensity scores of all
measured covariates.

We investigated the participation pattern of patients according to their service type and
frequency. We applied PCA to the estimated patient random effects from the ZIP model. The
first four components explained roughly 80% of the variability in types and frequency of
program services received, so we applied k-means clustering on these components, identifying
four clusters as the optimal solution. The clusters —of sizes 93 (20%), 130 (28%), 198 (42%),
and 46(10%) — appear in Figure 2-1. We calculated the proportion of participants attending the
different type of service as well as the average number of visits across clusters (Figure 2-2).
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Among all participants, the approximate proportion of participation in the 1:1 exercise is 50%,
20% for different group-activity sessions and psychology encounters, 45% for nutrition
counseling, over 80% for RN or SW encounter, and less than 5% in mid-level provider encounter
and genetic counseling. The average number of visits of any type of service is 10.1, respectively
5 for 1:1 exercise session, 1 for nutrition counseling, psychology encounter, RN or SW
encounter, and less than 1 for the other types of services. On average, participants spent 161 days
on the program.
The clustering identifies different participation patterns: Patients in Cluster 1 received
services related to exercise and diet lifestyle behaviors; 97% of the participants in Cluster 1
participated in a 1:1 exercise session where the average session count exceded 11; 86%
participated in nutrition counseling with an average participation count of 2.6. Cluster 2 engaged
in multiple types of sessions: 61% participated in 1:1 exercise with an average visit count of 7.4;
55% of them attended nutritional counseling, and around 40% participated in group-activity
sessions. Cluster 3 opted for sessions involving interaction with nurses (97%) and social workers
(90%); the frequencies for other types of service were all less than average. Cluster 4 gravitated
toward group-activity sessions; rather than individual RN or SW encounters (around 25%), they
preferred group-activity sessions (over 80% in all different group-activity session). The average
number of visits of any type of service is 19.7, 15.3, 3.3 and 5.5 for Cluster 1, 2, 3, 4 respectively
with average participation period as 165, 405, 32 and 18 days long respectively.
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Figure 2-1. k-means clusters visualized in principal components coordinates. (PC1-PC4: the first
four principal components)
Next, we analyzed ED visits. Most survivors (85%) had no ED visits, including nonparticipants (85%), participants before program (84%) and participants after the program (86%).
Corresponding to non-participants, participants before the program and participants after
program, the proportion of survivors who had 1 to 4 ED visits is 9.3%, 11.9% and 10.1%; the
proportion of survivors who had more than 4 ED visits is 4.7%, 3.9% and 3.8%, respectively.
We used the mixed ZIP model to examine the impact of the survivorship program on ED
visits. We first estimated the effect of any program participation. The ratio of ED counts of
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participants in the program to that of participants before the program and non-participants was
0.63 (95% CI: 0.48 – 0.81), which means participation was associated with a 37% reduction in
the number of ED visits (Figure 2-3, left panel). These models kept the zero-inflation proportion
the same regardless of participation status; allowing it to differ by participation status gave
similar results (not shown). We then examined, among participants, whether cluster membership
had an effect on ED visits. The number of ED visits after program to that before program is 0.44
(95% CI: 0.28 – 0.72), 0.51 (95% CI: 0.36 – 0.74), 1.26 (95% CI: 0.88 – 1.82) and 0.88 (95% CI:
0.48 – 1.59) respectively for Clusters 1, 2, 3 and 4 (Figure 2-3, right panel). These results
demonstrate that those who intensively participated in 1:1 exercise and nutrition counseling
sessions (Cluster 1), as well as those who participated in a multiple, mixed types of sessions
(Cluster 2) had significantly lower ED visit rate after vs. before program participation.
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A

B

Figure 2-2. Participation in different type of survivorship services by cluster type. Panel A shows
the proportion of all visits by visit type and Panel B shows the average number of visits by visit
type.
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Figure 2-3. Effect of participation in the survivorship program on ratio (the number of ED visits
in the intervention group to that in the reference group) of emergency department (ED) visits.
Panel A shows the effect of participants in the program vs. participants before program and
matched non-participants (reference group). Panel B shows the effect of different clusters of
participation among participants only, comparing the ratio of ED visits after program
participation to the ratio before program participation (reference group). A ratio of 1.0 indicates
that the number of ED visits in the intervention group is the same as the reference group. A ratio
less than 1.0 demonstrates fewer ED visits in the intervention vs. reference group.

2.4

Discussion
In 1986, the National Coalition for Cancer Survivorship (NCCS) was founded to establish

programs to help cancer survivors deal with the long-term effects of their disease and its
treatment.35 The Institute of Medicine (IOM) has provided guidance for the implementation of
comprehensive cancer survivorship care plans.28,29,36 Researchers have studied cancer
survivorship from a range of perspectives.37 Wattchow et al.38 found that colon cancer patients
with follow-up led by surgeons or general practitioners experience similar outcomes regarding
quality of life, anxiety and depression, and patient satisfaction. Knowles et al.39 demonstrated
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that a nurse-led model for colorectal cancer survivors was safe, efficient and cost-effective. In a
randomized trial, Grunfeld et al.40 found that receiving a survivorship care plan (SCP) did not
improve breast cancer survivors' distress. Nevertheless, much remains unknown, and there is a
pressing need for evidence-based guidance regarding the types and frequency of survivorship
services, along with which models of survivorship care improve patient outcomes.
Prior studies investigated the effects of survivorship program participation and number of
cancer follow-up providers on the occurrence of ED visits.41,42 To our knowledge, there has been
no study classifying survivorship program participants according to their patterns of use of the
different types of service, not to mention analyzing the association between these patterns and
the frequency of outcomes such as ED visits. Our study also goes beyond prior studies by
focusing on low-income, under- and uninsured patients, including multiple disease sites, and by
using propensity scores to account for differences between participants and non-participants.
We demonstrated participation in the MCI survivorship program is significantly associated
with lower rates of ED visits. The exact mechanisms for this effect are not known. It is possible
the services provided may reduce ED visits by lessening the severity of medical conditions
needing urgent care. It is also possible participants are seeking advice or care from program
personnel before their condition worsens to the point where an ED visit is necessary. Several
studies have shown the frequency of ED visits among cancer survivors exceed those of the
general population.43-45 Moreover, Panattoni et al.46 found 49.8% of ED visits in a commercially
insured oncology population had a potentially preventable cancer-related diagnosis with a related
median reimbursement of $1,029 per ED visit. Our findings suggest a survivorship program can
provide an opportunity to prevent avoidable ED visits. The cost-effectiveness of this approach is
unknown and deserves further study47.
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We also demonstrated distinct utilization patterns among survivors. We identified four
clusters, perhaps reflecting differences in patient interests or preferences for services, or perhaps
the availability and accessibility of different services. Participants in two of the four clusters had
reductions in ED visit rates by roughly half after beginning participation. This suggests the most
effective program components may be associated with these clusters: 1:1 exercise sessions,
nutrition sessions, etc.
Our study had several strengths. Linking the three data sources allowed us to analyze
patterns and effectiveness of cancer survivorship program use, to characterize and classify
survivorship program usage, and to evaluate the effectiveness of program participation using ED
visits. Our study also has several limitations. Because survivorship programs vary across
institutions, our results may not be relevant to different programs. Also, ED visits were captured
within a single healthcare system and survivors could have been seen elsewhere. However,
because this population is low-income, under- or uninsured, and received all or most of their
cancer diagnosis and treatment at JPS, and because JPS is the only integrated safety-net system
in the county, this seems like an unlikely scenario. In addition, as an observational study,
unobserved confounding may bias our results.
In conclusion, our study provides useful information for health care providers and cancer
centers to guide development, implementation, and outcome evaluations for future cancer
survivorship programs. These findings also provide evidence for insurers and payors to design
benefits, policies, and reimbursement mechanisms to facilitate coverage. Future studies will
evaluate the effect of survivorship program participation on other health service utilization, like
the uptake of cancer screening and surveillance tests.
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Among newly diagnosed cancer patients, those who survived a previous cancer have been
reported to live longer than those with no previous cancer. Possible explanations for this
phenomenon are lead-time bias and true biological effects. We propose a discrete competing-risk
model with adjustment for lead-time bias to describe the effect of a previous, non-lung cancer
diagnosis on the cause-specific survival of patients with lung cancer. We assume that the
observed survival for patients with previous cancer is the sum of lead time and post-lead-time
survival. We describe the former with a negative binomial distribution, and the latter with a
discrete cause-specific hazard, modeled as the inverse logit of a spline function on time. We
assume that post-lead-time survival in patients with no previous cancer differs from that in
cancer survivors by an odds ratio parameter. We applied our model to propensity score-matched
linked SEER–Medicare data. We estimate mean lead time to be less than one month at all lung
cancer stages; the effect of including lead time on estimates of group differences is modest.
Patients with a previous cancer had significantly lower hazard for lung-cancer death and noncancer death than patients without a previous cancer. Under a competing-risk model, lead-time
bias is modest, and does not explain differentials in cause-specific survival between lung cancer
patients with and without previous cancer. Patients with previous cancer have reduced hazards
of both lung-cancer and non-cancer mortality, but many die of their original tumors.
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3.1

Introduction
The number of cancer survivors is growing rapidly, leaving more of them at risk of a second

primary cancer.1,25 Lung and bronchus cancers are the leading cause of cancer-related death in
the US.1 Roughly 20% of patients aged 65 and over with a new diagnosis of a respiratory cancer
have experienced a previous cancer of some other kind.25
Several studies have investigated the impact of a previous cancer diagnosis on survival in
lung cancer and other diseases. Curiously, among lung cancer patients older than 65 years, those
with a history of a previous cancer had similar or better all-cause survival, depending on the
stage of lung cancer. Across all stages of lung cancer, those with a previous cancer had on
average longer lung cancer-specific survival.2-4
A possible explanation for this observation is lead-time bias, which occurs when
surveillance advances the date of diagnosis of a disease. In cancer, we typically define lead time
to be the difference between the date of diagnosis when observed through screening and the
(latent) date at which the diagnosis would have occurred without screening.48-51 For lung cancer
patients with a history of cancer, it is possible that a lead time could arise through enhanced
surveillance. That is, cancer survivors who harbor an as yet undiagnosed lung tumor could have
that tumor discovered early through additional testing they undergo as follow-up to their
previous cancer.52 Lead-time bias occurs when the diagnosis date is advanced such that mean
survival time appears to be longer, even when no survival advantage exists.
In a previous article, we proposed a statistical model for lead-time bias and survivorship,
and observed that even after accounting for lead time, time to death from lung cancer was
significantly longer for patients with a previous cancer diagnosis.52 Our method of analysis did
not, however, account for competing risks of death, in that it treated all non-lung cancer deaths
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as censoring events. This approach has several weaknesses: First, it implicitly assumes that the
latent times of death from each cause are statistically independent, an assumption that is
impossible to evaluate robustly.53 Indeed, it is more plausible that latent death times are
positively correlated, reflecting different levels of frailty, in which case estimates of survival
assuming independence are biased upward.54 Second, the survival curve assuming latent,
independent death times estimates the survival curve that would occur if we could eliminate the
competing causes of death. This is problematic because there is no reason to believe that
eliminating non-lung cancer causes of death would leave lung cancer death times unaffected.
Thus, not only the validity but the relevance of these estimates is questionable. Finally, we note
that our estimates of mean lead time differed by survival outcome (death from any cause vs.
death from lung cancer), possibly reflecting these biases and suggesting the need for a
comprehensive approach to modeling lead time and cause-specific survival.52
As early as 1957, Cornfield55 observed that the existence of competing risks complicates the
interpretation of cause-specific mortality rates. Prentice et al.56 proposed to study the
interrelations among competing causes of failure through cause-specific hazard functions, which
one can estimate without the need for unverifiable assumptions. Later, Fine and Gray18 proposed
a proportional hazards model to estimate the cumulative incidence of a competing risk. Yet
Austin and Fine57 observed that despite these advances, fewer than 20% of randomized trials in
which competing risks data arise present a competing-risks analysis.
Although it is typical to treat survival data as though they are continuous, in fact they are,
like all data, essentially discrete. With Surveillance, Epidemiology, & End Results (SEER)Medicare cancer survival data, for example, diagnosis and survival dates are only accurate to the
nearest month. Thus, many such observations may have equal, or “tied”, survival times, a
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circumstance that complicates the analysis of data that we assume to be continuous. Tutz58
proposed a discrete competing-risks model that one can estimate in the framework of the
generalized linear model. Ambrogi et al.59 proposed to estimate cumulative incidences through
multinomial logit regression analysis of discrete cause-specific hazards.
In this article, we propose a discrete competing-risk model to estimate the cause-specific
hazard for lung cancer patients with a previous diagnosis of cancer. We adjust our results by
assuming that lung cancer diagnosis time in survivors of a previous cancer is potentially subject
to a lead-time bias. We model the cause-specific hazards as inverse logits of linear splines on
time, assuming that a previous cancer diagnosis affects the cause-specific hazard through an odds
ratio factor. We assume that the lead time follows a negative binomial distribution and is
independent of the latent survival time. We estimate the mean lead time, the odds ratios of the
cause-specific hazards, and the cause-specific cumulative incidence rates by maximum
likelihood, applying our method to linked SEER-Medicare data on lung cancer patients.
3.2

Methods
Data Source
We used linked 1992–2011 National Cancer Institute SEER program files and 1991–2013

Medicare claims files from the Centers for Medicare & Medicaid Services. The Institutional
Review Board of the University of Texas Southwestern Medical Center approved our study.
Study Population
We included patients older than 65 years with primary lung cancer diagnosed between 2000
and 2011. All patients had full coverage of Medicare Parts A and B from 1 year before to 1 year
after the lung cancer diagnosis. We included only patients with either non–small cell (NSCLC)
or small cell (SCLC) lung cancer histology. To ensure complete claims data, we excluded
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patients who participated in health maintenance organizations and those with only autopsy or
death certificate records. We omitted patients with incomplete diagnosis or death dates or
discrepancies in SEER and Medicare birth dates of a year or more. We also excluded those who
developed another cancer after the index lung cancer.
We divided the patients into two groups: Those with a history of cancer (the Previous group)
and those without (the No-Previous group). The Previous group included those who had only
one previous, invasive, primary cancer that was not a lung cancer. We stratified patients by
American Joint Committee on Cancer lung cancer stage, grouping them into stages I&II, III, and
IV, and excluding the heterogeneous “unstaged” stratum.
Measures
We assumed three possible competing causes of death: The previous cancer (possible for
the Previous group only), the index lung cancer, and non-cancer causes. We measured survival
as the interval in months between the lung-cancer diagnosis and the date of death derived from
SEER.
To reduce confounding of previous cancer status with other potential correlates of mortality,
we created a set of patients in the No-Previous group who were matched to the Previous group
members. We matched on a propensity score that predicted previous cancer status from
available potential confounders in the SEER-Medicare database: Age, sex (F,M), race/ethnicity
(white, black, Hispanic, other), marital status (married, separated/divorced/widowed, single,
unknown), histology (SCLC, NSCLC-adenocarcinoma, NSCLC-squamous, NSCLC-other),
Charlson comorbidity score (0, 1, 2+, not available), Medicaid status (Y, N), and lung cancer
treatment (surgery only, chemotherapy only, radiation only, ≥2 treatments, no
surgery/chemo/radiation).
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Statistical Analysis
We propose a discrete competing-risk model to describe the cause-specific hazards in the two
groups defined by prior cancer status. We assume that there is a standard survival measure —
the time from clinical diagnosis to death — that we denote post-lead-time survival and label 𝑋𝑁
for subjects in the No-Previous group and XP for subjects in the Previous group. Because there
is, by definition, no possibility of lead-time bias in the No-Previous group, we observe XN
directly. In the Previous group, the observed survival is the sum of two independent
components: The notional post-lead-time survival XP and a random lead time T≥0 that is a
consequence of additional surveillance that patients undergo as a result of the previous cancer.
We see neither XP nor T directly; rather we observe their sum, which we denote Z=XP+T.
The cause-specific hazard for cause r in the No-Previous group is defined as ℎ𝑁𝑟 (𝑥) =
Pr(𝑋 = 𝑥, 𝑅 = 𝑟|𝑋 ≥ 𝑥). We model it with a linear spline on the logit scale:
ℎ𝑁𝑟 (𝑥) =

exp[𝜂𝑁𝑟 (𝑥)]
,(1)
1 + ∑𝑅𝑟=1 exp[𝜂𝑁𝑟 (𝑥)]
𝑚𝑟 +1

𝜂𝑁𝑟 (𝑥) = 𝛽0𝑟 + 𝛽1𝑟 𝑥 + ∑ 𝛽𝑗𝑟 (𝑥 − 𝑘𝑟 𝑗−1 ) ,(2)
+

𝑗=2

where mr is the number of knots; βjr, j=0,…,mr are the spline coefficients; 0 < 𝑘𝑟 1 < ⋯ < 𝑘𝑟 𝑚𝑟
are the spline knots; and (𝑢)+ = max(0, 𝑢). We model the cause-specific hazard in the Previous
group as 𝜂𝑃𝑟 (𝑥) = 𝜂𝑁𝑟 (𝑥) + γ𝑟 ; with this specification, OR 𝑟 = exp(γ𝑟 ) is the odds ratio of
hazards comparing the Previous to the No-Previous group. The overall hazard at time x in the
No-Previous group is ℎ𝑁 (𝑥) = ∑𝑅𝑟=1 ℎ𝑁𝑟 (𝑥); the overall survival function is 𝑆𝑁 (𝑥) =
Pr[𝑋𝑁 ≥ 𝑥] = ∏𝑗<𝑥[1 − ℎ𝑁 (𝑗)]; the cause-specific probability mass function is 𝑓𝑁𝑟 (𝑥) =
ℎ𝑁𝑟 (𝑥)𝑆𝑁 (𝑥); and the cumulative incidence rate is 𝐹𝑁𝑟 (𝑥) = ∑𝑗<𝑥 𝑓𝑁𝑟 (𝑗).
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We calculate the probability mass function of the latent 𝑋𝑃 similarly. To derive a
distribution for Z, the observable time from diagnosis to death in the Previous group, we first
assume that lead time 𝑇 follows the negative binomial distribution 𝑇~𝑁𝐵(𝜌, 𝜎), with
Γ(𝑡+𝜌)

probability mass function parameterized as 𝑓𝑇 (𝑡; 𝜌, 𝜎) = Γ(𝜌)Γ(𝑡+1) 𝜎 𝜌 (1 − 𝜎)𝑡 for ρ>0 and
0<σ≤1. Then the probability mass function of 𝑍 is the convolution of the densities of 𝑋𝑃 and 𝑇:
𝑓𝑍𝑟 (𝑧) = ∑𝑧𝑡=0 𝑓𝑇 (𝑡)𝑓𝑃𝑟 (𝑧 − 𝑡). The cumulative incidence rate is therefore 𝐹𝑍𝑟 (𝑧) = ∑𝑗<𝑧 𝑓𝑍𝑟 (𝑗),
and the overall survival is 𝑆𝑍 (𝑧) = 1 − ∑𝑅𝑟=1 𝐹𝑍𝑟 (𝑧).
The loglikelihood for the matched dataset is
𝑛𝑁

𝑅

𝑅

ln 𝐿(𝛽, 𝛾, 𝜌, 𝜎) = ∑ [∑ 𝑑𝑖𝑁𝑟 ln 𝑓𝑁𝑟 (𝑥𝑖 ; 𝛽) + (1 − ∑ 𝑑𝑖𝑁𝑟 ) ln 𝑆𝑁 (𝑥𝑖 ; 𝛽) ]
𝑖=1 𝑟=1
𝑛𝑃

𝑟=1

𝑅

𝑅

+  ∑ [∑ 𝑑𝑖𝑃𝑟 ln 𝑓𝑍𝑟 (𝑧𝑖 ; 𝛽, 𝛾, 𝜌, 𝜎) + (1 − ∑ 𝑑𝑖𝑃𝑟 ) ln 𝑆𝑍 (𝑧𝑖 ; 𝛽, 𝛾, 𝜌, 𝜎) ] ,(3)
𝑖=1 𝑟=1

𝑟=1

where 𝑛𝑁 and 𝑛𝑃 are the numbers of patients in No-Previous and Previous groups, respectively;
and 𝑑𝑖𝑁𝑟 and 𝑑𝑖𝑃𝑟 are indicators of whether patient 𝑖 died from cause 𝑟 in the No-Previous group
and Previous group, respectively.
We choose the spline knot locations by lasso variable selection. We assume for each cause
of death that the knots are the same in the Previous and No-Previous groups. For lung-cancer
death and other-cause death, we identify knots using data from the No-Previous group only. For
previous-cancer death, we find knots using data from the Previous group only. Initially, we set
knots at every fifth centile of the empirical distribution function of the survival data. Using
Equation (2), we fit the linear spline on the empirical net hazard, using lasso variable selection to
choose at most another two knots besides 1 and 5th centile.
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We estimate the model parameters by using generic optimization functions in the R statistical
language.17 Having obtained maximum likelihood estimates of the parameters, we calculate
estimates and confidence intervals for the odds ratios of the cause-specific mortality hazards, the
mean lead time, and the cumulative incidence rate (CIR) for each event cause. The Online
Supplement provides additional details.
We conducted a range of sensitivity analyses: The basic model assumes three causes of
death: Lung cancer, prior cancer, and other. We also assumed a two-cause model in which we
grouped together the prior cancer and other causes as a single cause of death. To examine the
impact of lead-time bias in the two-cause model, we estimated the odds ratios assuming that
there was no lead-time bias.
3.3

Results
Among 173,635 eligible lung cancer patients, 42,994 (24.8%) were stage I&II; 50,084

(28.8%) were stage III; and 80,557 (46.4%) were stage IV. The proportions of lung cancer
patients who had only one previous cancer were 15.3%, 12.5% and 12.0% for stages I&II, III,
and IV, respectively. Before matching, previous cancer prevalence differed across measured
sociodemographic and clinical covariates; it was higher (P < 0.0001, Tables 3-1, S1, S2) in lung
cancer patients who were older, male and without Medicaid. A 1:1 propensity score matching
eliminated these imbalances. The remaining analyses use this matched dataset.
Table 3-2 displays proportions of patients according to cause of death and stage. Combining
the Previous and No-Previous groups, the proportion who died of any cause increased as stage
increased: 65.9%, 91.6%, and 97.1% for stages I&II, III, and IV, respectively. For death from
lung cancer the trend was similar: 39.0%, 71.6%, and 79.0% for stages I&II, III, and IV,
respectively. As more patients died of lung cancer in the higher stages, the proportion who died
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from non-cancer causes declined, 21.1%, 14.2%, and 10.6% for stages I&II, III, and IV,
respectively. The proportions of overall, lung-cancer, and non-cancer deaths were all higher in
the No-Previous group. In the Previous group, the proportion of patients who died from the
previous cancer also increased as lung cancer stage increased: 11.5%, 11.6%, and 14.9% for
stages I&II, III, and IV, respectively.
We computed estimates of the model parameters using the matched data. Figure 3-1 shows
estimated CIRs from the three-cause model. It is clear that as stage advanced, the CIR for lungcancer death (dashed line) increased, while the CIR for non-cancer death (dot dashed line)
decreased. The No-Previous group (black lines) had higher CIR for both lung-cancer death and
non-cancer death, compared to the Previous group (red lines). For the Previous group, in stage
I&II, the CIR for previous-cancer death (dotted line) is lower than that for non-cancer death; in
stage III, their difference decreased; in stage IV, the order is reversed as CIR for previous-cancer
death is higher than non-cancer death. For the No-Previous group, the CIR for previous-cancer
death is defined to be 0. We calculated the CIR for death from any cause by summing the causespecific CIRs. In stage I&II and stage III, the CIR of overall death (solid line) for the Previous
group is higher than that for the No-Previous group. In stage IV, the CIR of overall death for the
Previous group is slightly less than that for the No-Previous group.

Table 3-1. Characteristics of patients with stage I&II lung cancer.

Total (n)
Age
<75
75-85
≥85
Sex
Female
Male

Previous
6594

n (%)
No-Previous
36400

Matched No-Previous
6594

2811 (42.6)
3093 (46.9)
690 (10.5)

17491 (48.1)
15766 (43.3)
3143 (8.6)

2785 (42.4)
3107 (47.1)
702 (10.6)

2799 (42.4)
3795 (57.6)

18220 (50.1)
18180 (49.9)

2877 (43.6)
3717 (56.4)
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P value
Unmatched
Matched
<0.0001

0.88

<0.0001

0.17

Race
0.052
White
5839 (88.6)
32006 (87.9)
5848 (88.7)
Black
472 (7.2)
2541 (7.0)
468 (7.1)
Hispanic
50 (0.8)
341 (0.9)
48 (0.7)
Other
233 (3.5)
1512 (4.2)
230 (3.5)
Marital Status
0.00032
Married
3635 (55.1)
19015 (52.2)
3587 (54.4)
Sep/div/wid
2324 (35.2)
13655 (37.5)
2382 (36.1)
Single
416 (6.3)
2456 (6.7)
409 (6.3)
Unknown
219 (3.3)
1274 (3.5)
216 (3.3)
Histology
<0.0001
Adenocarcinoma
3294 (50.0)
16394 (45.0)
3302 (50.1)
Squamous
1927 (29.2)
11363 (31.2)
1911 (29.0)
Small cell
230 (3.5)
1369 (3.8)
237 (3.6)
NSCLS/other
1143 (17.3)
7274 (20.0)
1144 (17.3)
Charlson Score
0.00083
0
2490 (37.8)
13047 (35.8)
2465 (37.4)
1
2026 (30.7)
11494 (31.6)
2058 (31.2)
2+
1895 (28.7)
10570 (29.0)
1906 (28.9)
Not available
183 (2.8)
1289 (3.5)
165 (2.5)
Medicaid
<0.0001
Yes
851 (12.9)
6151 (16.9)
851 (12.9)
No
5743 (87.1)
30249 (83.1)
5743 (87.1)
Lung cancer
<0.0001
treatment
Surgery only
2507 (38.0)
15464 (42.5)
2518 (38.2)
Chemo only
191 (2.9)
857 (2.4)
195 (3.0)
Radiation only
1041 (15.8)
5261 (14.5)
1072 (16.3)
≥2 treatments
1421 (21.5)
6980 (19.2)
1374 (20.8)
No
1434 (21.7)
7838 (21.5)
1435 (21.8)
surg/chemo/rad
* Characteristics of patients with stage III and IV lung cancer appear in Tables S1 and S2.

0.99

0.77

0.98

0.72

1.0

0.86

Table 3-2. Mortality fraction by lung cancer stage and cause of death.
Stage
I&II
III
IV

Group
Total
No-Previous
Previous
Total
No-Previous
Previous
Total
No-Previous
Previous

Patients
13188
6594
6594
12500
6250
6250
19430
9715
9715

Deaths by cause (%)
Lung cancer
Non-cancer
5150 (39.0)
2790 (21.1)
2824 (42.8)
1593 (24.2)
2326 (35.3)
1197 (18.2)
8955 (71.6)
1773 (14.2)
4746 (75.9)
1015 (16.2)
4209 (67.3)
758 (12.1)
15354 (79.0)
2058 (10.6)
8153 (83.9)
1319 (13.6)
7201 (74.1)
739 (7.6)

Overall
8697 (65.9)
4417 (67.0)
4280 (64.9)
11450 (91.6)
5761 (92.2)
5689 (91.0)
18864 (97.1)
9472 (97.5)
9392 (96.7)

Previous cancer
-757 (11.5)
-722 (11.6)
-1452 (14.9)

Table 3-3 presents estimates of the mean lead time and the odds ratios of the cause-specific
mortality hazards comparing the Previous group to the No-Previous group; we omit the OR for
risk of death from previous cancer, which is by definition infinity. The estimated mean lead time
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is less than 1 month: 0.53, 0.96, 0.48 months for stages I&II, III and IV respectively. It is
interesting that the longest lead time is found in stage III, possibly because by the time stage I&II
lung cancer becomes clinically detectable, it has already progressed to stage III.60 After
adjustment for lead-time bias, the odds ratios are significantly less than 1 for lung-cancer death
(ORl) and non-cancer death (ORnc). This suggests that patients in the Previous group are
relatively resistant to mortality from the subsequent lung cancer and to non-cancer causes,
experiencing their greatest risk of death from previous tumors. Comparing the top and bottom
panels of the table, it is apparent that estimated cause-specific odds ratios are robust to inclusion
of lead time in the model.
The estimated cumulative incidence rate, mean lead time and odds ratios for the two-cause
data appear in Figure S1 and Table S3 in the Online Supplement. In the two-cause data,
estimates of mean lead time are modest and are similar to those in the three-cause data, as are
values of ORl. Combining previous-cancer and non-cancer death, odds ratios for other-cause
death for the previous group versus non-previous group are significantly larger than one at all
stages of lung cancer. This suggests that the competing risk from a previous cancer accounted for
the reduction of the hazard of lung cancer.
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Figure 3-1. Cumulative incidence rate of death by stage and cause of death in the three-cause
data for lung cancer patients with and without previous cancer.

Table 3-3. Estimated mean lead time (months) and odds ratios by cause of death and stage in the
three-cause competing risk data.
Lung cancer mortality
Non-cancer mortality
ORl (95% CI)
ORnc (95% CI)
Assuming lead time
I&II
0.53 (0.35, 0.72)
0.89 (0.86, 0.93)
0.89 (0.84, 0.94)
III
0.96 (0.40, 1.53)
0.95 (0.91, 0.99)
0.83 (0.77, 0.89)
IV
0.48 (0.03, 0.94)
0.88 (0.83, 0.92)
0.56 (0.51, 0.60)
Assuming no lead time
I&II
0
0.88 (0.85, 0.92)
0.86 (0.82, 0.91)
III
0
0.89 (0.87, 0.92)
0.84 (0.78, 0.89)
IV
0
0.82 (0.80, 0.84)
0.66 (0.62, 0.70)
ORl: Odds ratio of the lung cancer mortality hazard of the Previous group relative to the No-Previous group.
ORnc: Odds ratio of the non-cancer mortality hazard of the Previous group relative to the No-Previous group.
Lung cancer stage

3.4

Mean lead time
(95% CI)

Discussion
Applying our flexible, discrete-data competing-risk model to SEER-Medicare lung cancer

data, we observed that estimated mean lead times are modest — less than one month in all
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stages. Regardless of adjustment for lead-time bias, the results in the three-cause data
demonstrated that the hazards of both lung cancer death and non-cancer death are moderately
less among patients with previous cancer compared to those with no previous cancer. The twocause data further revealed that the competing risk of other causes accounted for the reduction of
hazard of lung-cancer death. Failure to adjust for lead-time bias results in modest
underestimation of odds ratios, but as the mean lead time is small, so is the effect of estimating it
on the OR parameters.
The estimates of mean lead time differ from those in our previous analysis,52 which ignored
the competing-risks aspect of the data. Our earlier estimates of the mean lead time for lung
cancer survival were 11.3, 1.1, and 0.3 months for stages I&II, III and IV, respectively, whereas
under the three-cause model the corresponding estimates are 0.53, 0.96 and 0.48 months. We
conjecture that these discrepancies reflect a bias from ignoring competing risks. The largest
discrepancy is in stage I&II, where the percent of censoring from competing risks is highest, and
therefore there is the greatest opportunity for bias. Another possible explanation is that in the
data set for our competing-risks analysis we excluded patients with multiple previous tumors and
those who developed a second tumor after the index lung cancer. These exclusions were
necessary to ensure the accuracy of measuring previous-cancer death. The excluded patients,
especially those with multiple previous tumors, could have had long lead times that would have
strongly influenced estimates in the original analysis. The large difference between these results
indicates that competing risks are a likely source of bias in future studies about the survival of
patients with multiple cancers.
We estimated the lung cancer lead time to be short. In coming years, as lung cancer
screening becomes more routine, lead time for lung cancer in patients with previous cancers may
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increase. In patients with previous cancer who go on to develop other cancer types with
recommended early detection methods, such as breast, cervical, and colorectal cancer, lead times
may be larger. As our proposed model handles bias from both competing risks and lead time, we
advocate its application in future studies about the prognosis of cancer patients with multiple
cancers.
Several studies have applied the Fine-Gray18 competing-risk model to analyze the mortality
of cancer patients with a history of previous cancer.61,62 To our knowledge, none has proposed a
discrete competing-risk model and none has further adjusted for lead-time bias.
Our study has some limitations. First, SEER records a limited set of baseline variables, and
the absence of possible confounders may bias our estimates of the odds ratios on the causespecific hazards. Most prominently, SEER does not include smoking status, which is associated
with lung cancer, other cancers, and survival. Second, to reduce confounding, we applied our
model to matched data. This simplified computations but prevented us from assessing the effects
of these variables on mortality. Future studies could consider hazard models that include these
predictors, both as a way to better describe mortality and to exploit all available observations.
Third, we did not differentiate the types of previous cancers. Clearly, the previous cancer type is
a powerful predictor of survival; early-stage breast cancer has a far better prognosis than, say,
advanced pancreatic cancer.62,63 Finally, our analysis relies on assumptions regarding the form
of the joint distribution of the latent lead time and post-lead time survival. Previous analyses
with a similar model, however, suggested that conclusions are only moderately sensitive to these
untestable assumptions.52
In conclusion, under a discrete competing-risk model, the estimated mean lead time is less
than one month for all stages of lung cancer. Both with and without adjustment for lead time, the
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Previous group had a significantly lower hazard for both lung cancer and non-cancer mortality.
Evidently, the different survival outcomes seen in the Previous and No-Previous groups
represent true differences in mortality, and not a lead-time bias.
The number of cancer survivors in the U.S. is large and growing; as life expectancy for this
population increases,63 the U.S. will face a rising number of patients diagnosed with multiple
primary cancers. Careful consideration of the prevalence and impact of multiple primary cancers
on cancer outcomes is needed to ensure accurate estimation of mortality in descriptive cancer
epidemiology. More importantly exclusion criteria in lung cancer clinical trials, which
frequently prevent participation of patients with previous cancer,2 should be carefully
reconsidered in light of the observed survival advantage for lung cancer and non-cancer cause of
death for this large, growing population of newly diagnosed patients with previous cancers.
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APPENDIX

Table S1. Characteristics of patients with stage III lung cancer.

Total (n)

Previous
6250

n (%)
No-Previous
43834

Matched No-Previous
6250

Age
<75
75–85
≥85

2383 (38.1)
2996 (47.9)
871 (13.9)

20128 (45.9)
18667 (42.6)
5039 (11.5)

2391 (38.3)
3023 (48.4)
836 (13.4)

Sex
Female
Male

2424 (38.8)
3826 (61.2)

20586 (47.0)
23248 (53.0)

2429 (38.9)
3821 (61.1)

Race
White
Black
Hispanic
Other

5415 (86.6)
550 (8.8)
44 (0.7)
241 (3.9)

37360 (85.2)
3975 (9.1)
487 (1.1)
2012 (4.6)

5455 (87.3)
520 (8.3)
42 (0.7)
233 (3.7)

Marital Status
Married
Sep/div/wid
Single
Unknown

3371 (53.9)
2278 (36.4)
406 (6.5)
195 (3.1)

21471 (49.0)
17626 (40.2)
3162 (7.2)
1575 (3.6)

3377 (54.0)
2257 (36.1)
424 (6.8)
192 (3.1)

Histology
Adenocarcinoma
Squamous
Small cell
NSCLS/other

2264 (36.2)
1535 (24.6)
785 (12.6)
1666 (26.7)

13731 (31.3)
11095 (25.3)
6288 (14.3)
12720 (29.0)

2244 (35.9)
1484 (23.7)
819 (13.1)
1703 (27.2)

Charlson Score
0
1
2+
Unavailable

2369 (37.9)
1851 (29.6)
1813 (29.0)
217 (3.5)

16408 (37.4)
12864 (29.3)
11957 (27.3)
2605 (5.9)

2405 (38.5)
1849 (29.6)
1802 (28.8)
194 (3.1)

Medicaid
Yes
No

877 (14.0)
5373 (86.0)

8646 (19.7)
35188 (80.3)

910 (14.6)
5340 (85.4)
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P value
Unmatched
Matched

<0.0001

0.65

<0.0001

0.93

0.00084

0.76

<0.0001

0.92

<0.0001

0.56

<0.0001

0.66

<0.0001

0.40

Lung cancer treatment
Surgery only
Chemotherapy only
Radiation only
≥2 treatments
No surg/chemo/rad

0.028
326 (5.2)
710 (11.4)
984 (15.7)
2170 (34.7)
2060 (33.0)

2184 (5.0)
4451 (10.2)
6782 (15.5)
15580 (35.5)
14837 (33.8)

0.88

340 (5.4)
702 (11.2)
949 (15.2)
2170 (34.7)
2089 (33.4)

Table S2. Characteristics of patients with stage IV lung cancer.

Total (n)

Previous
9715

n (%)
No-Previous
70842

Matched No-Previous
9715

Age
<75
75–85
≥85

3822 (39.3)
4651 (47.9)
1242 (12.8)

33932 (47.9)
29571 (41.7)
7339 (10.4)

3820 (39.3)
4649 (47.9)
1246 (12.8)

Sex
Female
Male

3622 (37.3)
6093 (62.7)

33233 (46.9)
37609 (53.1)

3591 (37.0)
6124 (63.0)

Race
White
Black
Hispanic
Other

8387 (86.3)
859 (8.8)
94 (1.0)
375 (3.9)

60596 (85.5)
6055 (8.5)
846 (1.2)
3345 (4.7)

8410 (86.6)
830 (8.5)
94 (1.0)
381 (3.9)

Marital Status
Married
Sep/div/wid
Single
Unknown

5284 (54.4)
3454 (35.6)
656 (6.8)
321 (3.3)

34619 (48.9)
27864 (39.3)
5814 (8.2)
2545 (3.6)

5290 (54.5)
3453 (35.5)
665 (6.8)
307 (3.2)

Histology
Adenocarcinoma
Squamous
Small cell
NSCLS/other

3336 (34.3)
1530 (15.7)
1668 (17.2)
3181 (32.7)

22742 (32.1)
10239 (14.5)
13212 (18.6)
24649 (34.8)

3296 (33.9)
1532 (15.8)
1641 (16.9)
3246 (33.4)

Charlson Score
0
1
2+
Unavailable

3946 (40.6)
2772 (28.5)
2649 (27.3)
348 (3.6)

28555 (40.3)
19864 (28.0)
17371 (24.5)
5052 (7.1)

3991 (41.1)
2763 (28.4)
2592 (26.7)
369 (3.8)

Medicaid
Yes
No

1372 (14.1)
8343 (85.9)

13365 (18.9)
57477 (81.1)

1378 (14.2)
8337 (85.8)
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P value
Unmatched
Matched

<0.0001

0.88

<0.0001

0.17

0.00028

0.99

<0.0001

0.77

<0.0001

0.98

<0.0001

0.72

<0.0001

1.0

Lung cancer treatment
Surgery only
Chemotherapy only
Radiation only
≥2 treatments
No surg/chemo/rad

<0.0001
150 (1.5)
1502 (15.5)
2058 (21.2)
2261 (23.3)
3744 (38.5)

909 (1.3)
9948 (14.0)
15142 (21.4)
16143 (22.8)
28700 (40.5)

0.86

151 (1.6)
1445 (14.9)
2093 (21.5)
2275 (23.4)
3751 (38.6)

Figure S1. Cumulative incidence rate by stage and cause of death in the two-cause data for lung
cancer patients with and without previous cancer.

69

Table S3. Estimated mean lead time (months) and odds ratios by cause of death and stage in the
two-cause competing risk data.
Lung cancer
stage

Mean lead time (95% CI)

I&II
III
IV

0.60 (0.11, 1.10)
0.76 (0, 1.55)
0.43 (0.09, 0.77)

I&II
III
IV

0
0
0

ORl (95% CI)
Assuming lead time
0.90 (0.87, 0.94)
0.94 (0.89, 0.99)
0.87 (0.83, 0.91)
Assuming no lead time
0.88 (0.85, 0.92)
0.89 (0.86, 0.92)
0.82 (0.80, 0.84)

ORo (95% CI)
1.41 (1.34, 1.48)
1.59 (1.48, 1.71)
1.64 (1.54, 1.74)
1.39 (1.33, 1.46)
1.51 (1.43, 1.60)
1.56 (1.49, 1.64)

ORl: Odds ratio of the lung cancer mortality hazard of the Previous group relative to the No-Previous group.
ORo: Odds ratio of the other (non-cancer and previous cancer) mortality hazard of the Previous group relative to the
No-Previous group.

70

